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Abstract 
 CT Perfusion (CTP) is a minimally invasive imaging technique that aids acute ischemic 
stroke (AIS) triage and prognostication by determining tissue viability based on hemodynamic 
parameters.  The goals of this research are to determine: 1) CTP thresholds for estimation of 
infarct and penumbra volume, 2) how CTP scan duration impacts infarct and penumbra volume 
estimates, and 3) reliability of CTP for predicting functional outcomes following intra-arterial 
therapy (IAT). 
 Chapter 2 introduced an experimental study for determining ischemia-time dependent 
thresholds for brain infarction using multimodal imaging in a porcine stroke model that is 
easier to implement than previous large animal stroke models.  CTP determined an absolute 
cerebral blood flow (CBF) threshold of 12.6±2.8mL∙min-1∙100g-1 for brain infarction after 3h 
of ischemia, which was close to that derived using hydrogen clearance in a previous study by 
Jones et al (Journal of Neurosurgery, 1981;54(6):773-782). 
 Chapter 3 retrospectively investigated the impact of CTP scan duration on cerebral 
blood volume (CBV), CBF, and time-to-maximum (Tmax) and found optimal scan durations 
that minimized radiation dose while not under- or over-estimating infarct volumes measured 
using two previously derived CBF thresholds for infarction.  We found that CBV and Tmax 
decreased at shorter scan durations, whereas CBF was independent of scan duration, 
consequently, infarct volume estimated by both CBF thresholds was independent of scan 
duration. 
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 Chapter 4 compared reperfusion seen on follow-up CTP to reperfusion predicted by 
post-IAT digital subtraction angiography (DSA) and the ability of the two modalities to predict 
good 90-day functional outcome in a retrospective study.  We found that patients with 
‘complete reperfusion’ grades on DSA often had ischemic tissue on follow-up CTP and that 
follow-up CTP had superior specificity and accuracy for predicting functional outcome 
compared to DSA. 
 In summary, this research has shown that CBF thresholds can reliably detect infarct in 
AIS and are independent of scan duration, allowing radiation dose to be minimized by limiting 
scans to 40s without compromising accuracy of infarct volume estimates.  Finally, CTP is a 
more specific and accurate predictor of functional outcome than the commonly used post-
procedural DSA, this could help select patients for neuroprotective therapy. 
Keywords 
Stroke, cerebral ischemia, computed tomography, computed tomography perfusion, functional 
imaging, cerebral blood flow, infarction, animal stroke model, mechanical thrombectomy. 
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Chapter 1  
1 Introduction 
 Stroke is the second leading cause of death, and third leading cause of disability 
worldwide1 according to the World Health Organization.  Overall, stroke mortality rates 
have declined over the last 30 years in the United States2, and Canada3, but incidence 
rates remain higher in certain racial4, and gender cohorts5, and in certain geographical 
areas6.  The decline in overall stroke mortality rate is due to a decrease in the number of 
fatal strokes7, rather than a decrease in stroke incidence, which is projected to more than 
double over the next 30 years, with most of the increase coming from people aged 75 
years or older8.  Approximately half the survivors of stroke are institutionalized or 
disabled within 5 years9, and due to the aging population, the number of individuals 
living with disability resulting from stroke is projected to almost double in the next 2 
decades10.  Long term care for these patients will further increase the socioeconomic 
burden of cerebrovascular disease11.  CT Perfusion (CTP) is a minimally invasive 
imaging technique that produces quantitative maps of hemodynamic parameters which 
can be used to assess tissue viability.  CTP could improve outcomes after stroke by 
allowing triaging based on each patients’ brain tissue viability, allowing the optimal 
treatment to be selected on an individualized basis.  Post treatment CTP is not commonly 
performed but could also be used to improve prognostication by quantitatively assessing 
reperfusion of ischemic tissue.  The goals of this research are to determine: 1) CTP 
thresholds for estimation of infarct and penumbra volume, 2) how CTP scan duration 
impacts infarct and penumbra volume estimates, and 3) the prognostic utility of CTP for 
predicting functional outcomes following intra-arterial therapy (IAT).  To lessen the 
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future socioeconomic burden of cerebrovascular disease, CTP-based acute treatment and 
patient-specific triaging and management must be improved to reduce the proportion of 
stroke patients living with severe disability following their stroke. 
1.1 Stroke Pathophysiology 
Stroke is caused by a reduction in blood flow to the brain and can be divided into 
two broad categories.  Hemorrhagic strokes are caused by leakage from damaged cerebral 
blood vessels, and ischemic strokes are caused by blockage of an artery supplying the brain 
tissue.  This thesis deals only with ischemic stroke and not hemorrhagic stroke.  Studies 
suggest that the overall annual incidence of first-ever stroke in North America is 189 per 
100,000 people, with ischemic strokes accounting for ~85% of the total incidence12.  
Approximately 30% of ischemic stroke patients die within 3 months of the stroke13, and 
~45% of survivors will not be able to live independently14. 
1.1.1 Cerebral Ischemia 
Cerebral ischemia is a condition where restricted cerebral blood flow (CBF) leads 
to insufficient supply of oxygen and glucose to meet the metabolic demands of brain tissue.  
Cerebral ischemia can be global, such as when cardiac arrest or open-heart surgery results 
in complete cessation of systemic blood flow, or focal, where CBF is reduced in one region 
of the brain15.  There are multiple arterial etiologies of focal cerebral ischemia.  The most 
common are thrombosis in situ, clot formation in a cerebral artery due to endothelial injury 
triggering the coagulation cascade; and thromboembolism, where emboli travel to cerebral 
vessels through the blood after rupture of a thrombus or atherosclerotic plaque elsewhere 
in the body16.  Cerebral emboli are also formed in the heart due to blood becoming static 
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during atrial fibrillation, or from coagulation following open heart surgery.  Sustained 
hypertension can lead to fibrinoid deposits within cerebral arterioles, which is often 
associated with lacunar infarction16.  Ischemia in tissue supplied by the distal part of the 
cerebral vascular tree is referred to as watershed stroke.  Watershed stroke is usually caused 
by decreased mean arterial pressure in the internal carotid arteries (ICA) due to myocardial 
dysfunction, systemic hypotension, or ICA stenosis17. 
The trial of Org 10172 in acute stroke treatment (TOAST)18 established a 
classification system which denoted five subtypes of ischemic stroke: large-artery 
atherosclerosis, cardioembolism, small-vessel occlusion, stroke of other determined 
etiology, and stroke of undetermined etiology19.  Strokes of different subtypes (as identified 
by TOAST criteria) can have varying clot composition, size, and density, which can impact 
stroke severity and response to acute treatment20,21.  Regardless of vascular etiology, 
reduced delivery of oxygen and glucose due to reduced CBF results in inadequate 
production of adenosine triphosphate (ATP) by cellular respiration.  Neuronal cells require 
ATP for active, facilitated transport of Na+, K+ and other ions to maintain their resting 
membrane potential, and for action potential propagation.  Intracellular ATP stores are 
exhausted within minutes post ictus, leading to loss of ionic homeostasis22, this is the first 
step in a complex ‘ischemic cascade’ which ultimately leads to cell death caused mainly 
by excitotoxicity, Ca2+ dysregulation, and oxidative/nitrative stress. 
Anoxic depolarization due to influx of Na+, and failure of normal reuptake 
mechanisms causes excessive accumulation of the excitotoxic neurotransmitter, glutamate, 
in the extracellular space23.  This leads to overstimulation of ionotropic glutamate 
receptors, resulting in a large influx of Ca2+, Na+, and water into neurons.  Accumulation 
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of intracellular Ca2+ is further exacerbated by other anion channels activated during 
ischemia24–26, and failure of normal Ca2+ efflux mechanisms, such as the Na+/Ca2+ 
exchanger27.  Influx of Ca2+ activates proteases, lipases, and nucleases28, and also leads to 
increased production of reactive oxygen species29.  These factors can trigger release of Ca2+ 
from the endoplasmic reticulum, as well as reactive oxygen species and enzymes from the 
mitochondria30, further accelerating the death spiral.  Continued build-up of metabolic, 
oxidative, and nitrative stressors eventually lead to cell death by necrosis or apoptosis.  
Glutamate excitotoxicity also expands the ischemic injury at a macroscopic level by 
causing cortical spreading depolarization, where elevated extracellular glutamate and K+ 
cause slowly propagating depolarization of surrounding neurons and astrocytes, and 
disruption of ionic gradients31.  Disruption of ionic gradients, and mismatch between 
reduced CBF and high metabolic demand to support membrane repolarization lead to 
expansion of the initial ischemic injury32. 
Cerebral blood vessels are separated from brain tissue by a selectively permeable 
barrier called the blood-brain barrier (BBB) which tightly regulates the passage of 
molecules between the blood and brain tissue.  The BBB consists of endothelial cells, 
astrocytic end-feet, pericytes and a basement membrane.  Tight junctions between adjacent 
endothelial cells and astrocytic end-feet form a physical barrier, allowing lipophilic 
molecules and metabolic products to cross by passive diffusion, and preventing diffusion 
of hydrophilic molecules, and potential neurotoxins33.  Pericytes embedded in the basement 
membrane envelope the endothelial cells interact closely with them and play a role in 
maintaining and regulating BBB function34.  Prolonged ischemia triggers several responses 
which compromise the integrity of the BBB.  In the acute phase of stroke, ischemia causes 
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pericytes to detach from endothelial cells, disrupting intercellular signalling interactions 
which results in blood-borne substances entering the brain via increased endothelial 
transcytosis35.  Ischemia also degrades tight junctions between endothelial cells, allowing 
molecules to travel out of the blood via paracellular diffusion36, and causes astrocytes to 
retract their end-feet and release pro-inflammatory cytokines37.  The longer the duration of 
ischemia, the more severe the BBB breakdown and inflammatory response.  This in turn 
increases the likelihood of blood extravasation if the ischemic tissue is eventually 
reperfused, a process known as hemorrhagic transformation of cerebral infarction.  
Furthermore, hyperglycemia caused by diabetes mellitus is known to worsen BBB 
breakdown, in addition to enhancing atherosclerosis, arterial stiffness, oxidative stress, and 
systemic inflammation38.  As a result, patients with diabetes mellitus are more likely to 
have ischemic strokes, and also have higher rates of hemorrhagic transformation39 and 
mortality 90 days post stroke40. 
Tissue fate in ischemic stroke is time dependent (this will be detailed in the next 
subsection); tissue remains viable after symptom onset, but ~1.9 million neurons become 
irreversibly damaged every minute that stroke symptoms persist41.  Treatment for acute 
ischemic stroke (AIS) revolves around salvaging viable ischemic tissue by restoring normal 
perfusion to the affected region as quickly as possible.  However, restoring CBF to 
ischemic tissue regions with a potentially compromised BBB can lead to hemorrhagic 
transformation.  For this reason, decisions surrounding the treatment of AIS are often 
determined by weighing the potential benefits of reperfusion, which declines over time42,43, 
against the risks of hemorrhagic transformation or other complications.  
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1.1.2 Tissue Subtypes in Ischemic Stroke 
 In neuronal cells, the energy requirements, and by extension the CBF requirements, 
for signal transduction (action potential propagation and neurotransmission) and 
maintaining morphological integrity are different44.  Consequently, tissue affected by focal 
ischemia in the acute phase of ischemic stroke can be classified into distinct categories 
based on blood flow thresholds.  Studies show there are two critical thresholds of decreased 
CBF: a threshold for reversible functional failure, and a lower threshold for irreversible 
morphological damage45. 
Tissue in the central, most hypoperfused region, with CBF below the threshold for 
irreversible damage, is termed the infarct core.  The definition of infarct core was originally 
based on substantial increases in extracellular K+ concentration seen in baboons when CBF 
was reduced by occlusion of the middle cerebral artery (MCA)45,46.  Increased extracellular 
K+ is a marker of anoxic depolarization, one of the early steps in the ischemic cascade 
which ultimately leads to necrosis or apoptosis, therefore the infarct core is irreversibly 
damaged and no longer viable, even with reperfusion.  In cases where cerebral circulation 
is completely arrested (e.g. cardiac arrest) brain infarction can occur within minutes, but 
when cessation of blood flow is not complete the time it takes for infarction to occur 
depends on the level of residual CBF.  Experiments in animal models established that for 
1 to 2 hours of ischemia, tissue with CBF less than 8-10 mL∙min-1∙100g-1 will become 
infarcted47,48. 
The tissue surrounding the infarct core, with CBF below the threshold for functional 
failure, but above the threshold to induce acute infarction, is termed the penumbra.  The 
concept of penumbra was based on observations that electroencephalography activity was 
7 
 
affected at a higher CBF level than the threshold for increased extracellular K+ in a baboon 
model of focal ischemia45,46.  Clinical49 and animal studies50,51 show that the CBF threshold 
for functional impairment ranges from 15-20 mL∙min-1∙100g-1, depending on the species 
and measurement method used.  Tissue with CBF between the thresholds for functional 
impairment and acute infarction will remain salvageable if normal blood flow is restored 
promptly.  As mentioned previously, the window for tissue viability before infarction 
becomes inevitable depends on the level of residual blood flow and the duration of 
ischemia52.  The threshold for infarction after 1 hour of ischemia is ~8 mL∙min-1∙100g-1, if 
ischemia persists for 3 hours the infarction threshold rises to ~12 mL∙min-1∙100g-1 47,48, if 
normal CBF is not restored and ischemia persists indefinitely, then all penumbral tissue 
will eventually progress to infarction48. 
Lastly, tissue with CBF that is lower than normal levels but still above the threshold 
for functional impairment is termed benign oligemia45.  Despite hypoperfusion, this tissue 
does not progress to infarction, regardless of the duration of ischemia, and is therefore not 
as clinically important as infarct or penumbra. 
The human brain is composed of two distinct types of tissue, gray and white matter.  
Gray matter mainly consists of neuronal cell bodies, unmyelinated axons, glial cells and 
synapses and is found in the cerebral cortex, thalamus, hypothalamus, and basal ganglia.  
White matter consists of myelinated axons, and glial cells and connects various gray matter 
regions together, allowing neuronal signals to be conducted through the brain quickly53.  
Resting CBF is lower in white matter (20-25 mL∙min-1∙100g-1) than gray matter (50-60 
mL∙min-1∙100g-1)54 because white matter consumes only about one third of the energy 
consumed by gray matter due to greater efficiency conducting action potentials and the 
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absence of synapses55.  Since white matter has a lower energy demand and perfusion level, 
it follows that CBF thresholds for infarction and electrical silence are also lower than in 
gray matter for a given ischemia duration.  Clinical studies have confirmed that the CBF 
threshold for infarction in gray matter is significantly higher than in white matter for similar 
ischemia durations56.  Therefore, using the same infarction thresholds for both white and 
gray matter may overestimate the volume of infarcted white matter56.   
1.2 Treatment of Ischemic Stroke 
Treatment of AIS was limited to medical management and basic life support until 
the introduction of thrombolytic therapy in 199657.  Current treatment of AIS is based on 
recanalization of the occluded artery to restore CBF to ischemic tissue.  There are two 
approved treatment options: thrombolytic therapy – which works by dissolving the clot via 
fibrinolysis, and mechanical thrombectomy – an interventional procedure where the clot is 
mechanically removed using a specialized catheter58.  Regardless of what treatment is used, 
initiating therapy as soon as AIS is diagnosed by imaging is crucial for maximizing 
penumbral salvage and lessening the risk of hemorrhagic transformation or other 
complications42,43.  Current clinical guidelines suggest implementing protocols such as pre-
arrival hospital notification of incoming patients with possible AIS59, or using telemedicine 
to accelerate image interpretation for rural centers without a neuroradiologist on site60, to 
minimize the delay between hospital admission and initiation of treatment (referred to as 
‘door-to-needle time’).  The goal of implementing such protocols is to perform CT within 
20 minutes of admission and keep door-to-needle times less than 60 minutes in at least 
50% of patients61. 
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1.2.1 Thrombolytic Therapy 
Thrombus formation (thrombosis) and dissolution (thrombolysis) are complex 
interconnected processes.  Thrombosis starts when platelets are activated by contact with 
sub-endothelial proteins62.  Activated platelets trigger a series of protease-mediated 
cleavages which ultimately ends with the serine protease thrombin cleaving soluble 
fibrinogen into insoluble fibrin63.  Fibrin polymerizes to form the bulk of the blood clot 
along with activated platelets, red blood cells, and white blood cells64.  This clotting 
cascade prevents excessive blood loss from damaged blood vessels but can also lead to 
thromboembolic stroke when clots form in cerebral arteries, or travel to cerebral arteries 
from elsewhere in the body.  Clot dissolution is mediated by endogenous fibrinolysis, 
which relies on the formation of plasmin, a fibrinolytic enzyme, from its precursor 
plasminogen.  This conversion is catalyzed by a group of enzymes called plasminogen 
activators65.  Thrombolytic therapy involves administering drugs that are either 
recombinant versions of endogenous plasminogen activators (e.g. tissue plasminogen 
activator (t-PA) or urokinase-plasminogen activator (u-PA)), or exogenous plasminogen 
activating agents (e.g. streptokinase), that enhance plasmin-mediated fibrinolysis65.  The 
likelihood of early recanalization and good outcome after IV thrombolysis is dependent on 
the clot fibrin content66, and its length and density on CT67,68.  Early vessel recanalization 
and good functional outcome are also more likely in cardioembolic strokes compared to 
other stroke subtypes69,70.  A significant drawback to thrombolysis is that degradation of 
fibrin and fibrinogen inhibits the coagulation cascade71, and therefore increases the risk of 
intracerebral hemorrhage (ICH)72.  Additionally, in patients with compromised BBB due 
to prolonged ischemia, t-PA can cross into the interstitial space, where it has neurotoxic 
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effects that can enhance excitotoxicity and further damage the BBB73.  For this reason, 
primary ICH must be ruled out by computed tomography (CT) or magnetic resonance 
imaging (MRI) before initiating thrombolysis74. 
The first clinical trial to show a significant benefit of thrombolytic therapy was the 
National Institute of Neurological Disorders and Stroke (NINDS) trial in 1995.  Alteplase, 
a recombinant version of t-PA was administered intravenously within 3 hours of symptom 
onset, in patients with no evidence of ICH on CT.  The percentage of patients with excellent 
outcome (assessed as a score of 0 or 1 on the modified Rankin Scale (mRS)) in the t-PA 
group was 43% compared to only 26% in the control group, and 90 day mortality was also 
lower in the t-PA group, despite increased risk of ICH (6.4% vs 0.6%)57.  Based on these 
results, the United States Food and Drug Administration (FDA) approved IV t-PA for the 
treatment of AIS within 3 hours post symptom onset.  Phase IV trials in Canada75 and 
Europe76 would later confirm the efficacy of IV t-PA in routine care settings, showing that 
rates of excellent outcome (mRS ≤ 1) (~38%), mortality within 90 days (11% to 22%), and 
symptomatic ICH (~6%) were all similar to pooled results from randomized controlled 
trials.   
In the decade after FDA approval, administration rates of IV t-PA remained as low 
as 0.9% to 2.4%77,78, with the 3 hour time window posing a significant barrier to 
treatment79.  Multiple trials comparing placebo to IV t-PA given within the first 6 hours 
post onset80,81, or in the 3 to 5 hour time window82, failed to show a significant 
improvement in functional outcome, and had higher rates of symptomatic ICH in the 
treatment group.  Meta-analysis of pooled data from six randomized controlled trials of IV 
t-PA found decreased odds of an excellent outcome (mRS ≤ 1) as onset-to-treatment times 
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increased, but there was still a significant benefit in the 3 to 4.5 hour time window83.  
Efficacy of IV t-PA given within 3 to 4.5 hours post onset was confirmed in the European 
Cooperative Acute Stroke Study (ECASS) III trial, which found significantly higher rates 
of excellent functional outcomes (52 vs 45% in the control group) in the IV t-PA group, 
and similar mortality rates despite increased risk symptomatic ICH84.  Administration of 
IV t-PA remains a frontline therapy for AIS patients, but the time window still presents a 
major barrier to treatment; studies suggest up to 67% of patients not receiving thrombolysis 
are deemed ineligible because of the time window85. 
Current clinical guidelines suggest administering IV t-PA within 4.5 hours of 
symptom onset, at a dosage of 0.9 mg/kg, with the first 10% of the dose given as a bolus58, 
although a dosage of 0.6 mg/kg may result in similar improvement in functional outcome 
with lower rates of symptomatic ICH86.  Patients can be treated regardless of age, or 
admission stroke severity (assessed by the National Institute of Health Stroke Scale or 
NIHSS), provided admission non-contrast CT (NCCT) rules out primary ICH74.  IV t-PA 
within 4.5 hours is currently indicated for both genders, but the treatment effect may be 
more beneficial in women than in men87.  Patients who are at risk of a serious bleeding 
complication due to recent stroke, head trauma, brain surgery, or administration of low 
molecular weight heparin within 24 hours preceding the stroke should not be treated with 
thrombolysis58.  Blood glucose must be measured before initiating thrombolytic therapy 
because hypoglycemia can be incorrectly diagnosed as AIS88, and severe hyperglycemia 
(blood glucose > 400mg/dL) is associated with lower recanalization rates89 and increased 
the risk of ICH and poor outcome90.  Consequently, diabetes mellitus is also associated 
with higher rates of hemorrhagic transformation91 and in-hospital mortality92 in AIS 
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patients treated with thrombolysis, though studies suggest diabetic AIS patients still benefit 
from IV t-PA93.  Hypertension is also associated with increased risk of hemorrhagic 
transformation following thrombolytic therapy, increased mortality, and decreased 
probability of good functional outcome94.  Hypertensive patients can only receive IV t-PA 
if systolic and diastolic blood pressure can be safely lowered to less than 185, and 
110mmHg respectively, and should be maintained at less than 180 and 105mmHg 
respectively for twenty-four hours after initiating thrombolytic therapy58. 
1.2.2 Mechanical Thrombectomy 
 Successful trials of IV thrombolysis were a breakthrough in treatment of AIS, but 
the time window still posed a major impediment to treatment85, and recanalization rates 
were poor for large vessel occlusions (LVO)95.  LVO refers to occlusions of large proximal 
cerebral arteries, such as the M1 segment of the MCA, anterior cerebral artery (ACA), 
distal ICA, or the basilar artery.  Although only ~40% of ischemic strokes are caused by 
LVO they account for ~60% of post-stroke dependence and ~95% of post-stroke 
mortality96.  Poor recanalization rates for LVO and the relatively short time window for 
administrating IV t-PA were major drivers for development of IAT for AIS. 
 Early attempts at IAT involved administering thrombolytic drugs directly to the 
thrombus by guiding an endovascular microcatheter delivery system to the occlusion site, 
allowing a high concentration of thrombolytic agent to be delivered to the thrombus while 
also minimizing systemic exposure, theoretically minimizing the risk of hemorrhage.  The 
earliest clinical use of IAT in the literature used intra-arterial (IA) delivery of streptokinase 
to treat patients with basilar artery thrombosis and reported excellent outcomes in 3 of 5 
patients97.  Later studies found that IA recombinant u-PA within 6 hours of onset was 
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associated with improved functional outcome98,99, but also high rates of ICH, and 
symptomatic ICH98,99.  Several studies also combined IV t-PA initiated as soon as possible, 
followed by IA delivery of t-PA directly to the thrombus for patients who still had clot 
visible on angiography.  These studies found similar rates of ICH and a nonsignificant 
improvement in outcome compared to IV t-PA alone100–102.  Although IA thrombolysis was 
shown to improve recanalization rates compared to IV thrombolysis98–103, there is no level 
1 evidence that IA thrombolysis alone improves functional outcome compared to IV 
thrombolysis alone. 
 Catheter devices for mechanically removing thrombus were developed as an 
alternative to IA delivery of thrombolytic agents.  Mechanical removal of the thrombus is 
advantageous because of high recanalization rates for LVO104, faster recanalization relative 
to IA thrombolysis which requires prolonged infusion of thrombolytic agents for up to 2 
hours102, and reduced hemorrhage risk by avoiding the use of thrombolytic drugs105.  In a 
mechanical thrombectomy procedure: a microcatheter is advanced to the occlusion site and 
passed through the thrombus, the device is deployed distal to the thrombus and retracted to 
ensnare the thrombus and pull it to a proximally placed guide catheter for aspiration106.  
The first endovascular device approved for AIS treatment used a flexible corkscrew design 
and was called the Mechanical Embolus Removal in Cerebral Ischemia (MERCI) 
retriever106.  Trials of the MERCI device showed that LVOs could be recanalized in 46% 
to 57% of patients treated within 8 hours, but design limitations meant up to 6 passes had 
to be made to remove the entire clot106,107.  Second generation devices using a flexible, 
retrievable wire stent were shown to be superior to the MERCI device108,109. 
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 Early randomized controlled trials of mechanical thrombectomy all failed to show 
a significant improvement in functional outcome compared to IV t-PA110–112, but these 
trials had several important limitations.  Only ~20% of patients in the IAT arm of each trial 
were treated with second generation devices110–112, and in 2 trials 50% to 66% of patients 
were treated with IA thrombolysis instead of thrombectomy110,111.  IV t-PA was not 
administered to patients randomized into the IAT arm of 1 trial.  As a result, treatment was 
initiated an average of 1h later in patients receiving IAT compared to patients treated with 
IV t-PA111.  CT angiography (CTA) was not used to confirm the presence of a LVO for all 
patients in 2 of the trials, resulting in many patients randomized into the IAT arm not 
having an occlusion that was suitable for treatment with IAT110,111.  Lessons learned from 
these trials informed the design of subsequent randomized, controlled trials of IAT. 
 In 2015, 5 trials comparing patients treated with IV t-PA plus IAT to patients treated 
with IV t-PA alone were stopped early after demonstrating significant benefit of IAT.  All 
5 trials used NCCT or MRI to rule out ICH, angiography to confirm the presence of LVO, 
and initiated IAT within 6113–116 to 8117 hours of symptom onset.  In addition to 
demonstrating the efficacy of IAT for treating patients with LVO, these trials also provided 
early evidence that advanced neuroimaging, such as multi-phase CTA or CTP could be 
used to identify patients with a small infarct core and large penumbra, who would be most 
likely to benefit from revascularization.  The ESCAPE trial, performed in Canada, used a 
semi-quantitative scale called the Alberta Stroke Program Early CT Score (ASPECTS) to 
assess NCCT for signs of early ischemic damage indicative of a large infarct core118, and 
a novel CTA imaging technique (multiphase CTA) to evaluate the degree of collateral 
circulation, which reflects the amount of residual CBF in the ischemic tissue119.  The 
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SWIFT-PRIME and EXTEND-IA trials, performed in the United States and Australia/New 
Zealand respectively, used thresholds applied to parameter maps from CTP to estimate the 
volume of infarct and penumbra; patients with large infarct volumes and/or small 
penumbra volumes were excluded113,115.  These trials, which included imaging to evaluate 
the extent of irreversibly damaged infarct and salvageable penumbra, had higher rates of 
good functional outcome in the IAT group (53% to 71%), than the MRCLEAN and 
REVASCAT trials, conducted in the Netherlands and Spain respectively, which did not 
use advanced neuroimaging (33% to 44%)116,117. 
 Several retrospective studies noted that there was no significant difference in the 
rate of good functional outcome, symptomatic ICH or mortality when patients were triaged 
based on admission CTP or MRI120,121, providing more support for image-based triaging 
rather than strictly time-based triaging.  The efficacy of image-based triaging for IAT was 
confirmed recently in the DEFUSE 3 and DAWN trials – two randomized, controlled trials 
comparing standard medical therapy alone to standard medical therapy plus IAT in patients 
arriving up to 16 hours122 to 24 hours123 post symptom onset, or those with unknown onset 
times.  Patients were eligible if they had LVO confirmed on CTA, no evidence of 
hemorrhage on NCCT, and mismatch between infarct volume and either penumbra 
volume122 or clinical deficit123.  The treatment effect of IAT (difference in rate of functional 
independence between IAT and control groups) seen in these trials (28% to 36%)122,123 was 
paradoxically larger than what was seen in a meta-analysis of the trials where IAT was 
initiated within 6 hours of symptom onset (19.5%)104.  This was mainly because patients 
in the control group were not eligible for IV t-PA since these trials only enrolled patients 
where time from symptom onset was 6 hours or more (87% of patients in the control groups 
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in earlier trials received IV t-PA)104.  Nevertheless, the rate of IAT-treated patients with 
good functional outcomes (45% to 49%)122,123 was similar to when IAT was initiated within 
6 hours of symptom onset (46%)104, showing that IAT could still be effective in certain 
patients up to 24 hours post symptom onset. 
 Current clinical guidelines recommend performing mechanical thrombectomy with 
a stent retriever within 6 hours of symptom onset in patients aged 18 years or older, no sign 
of extensive early ischemic damage on NCCT (ASPECTS ≥ 6), and occlusion of the 
intracranial portion of the ICA or M1 segment of the MCA confirmed on CTA58.  
Mechanical thrombectomy is also recommended up to 24 hours post symptom onset in 
patients aged 18 years or older, with CTA-confirmed occlusion of ICA or M1 segment of 
the MCA, and either an infarct/penumbra mismatch, defined by the DEFUSE 3 trial 
criteria, or a clinical/imaging mismatch, defined by the DAWN trial criteria.  Both trials 
used thresholds applied to CTP-CBF maps or diffusion-weighted MRI (diffusion-weighted 
imaging or DWI) to estimate the volume of infarct core.  The DEFUSE 3 trial used 
thresholds applied to time-to-maximum (Tmax) maps from CTP or perfusion-weighted MRI 
(perfusion-weighted imaging or PWI) to estimate the penumbra volume; patients were 
eligible for treatment if penumbra volume was 1.8 times larger than the infarct, infarct 
volume was < 70mL, and penumbra volume was > 15mL122.  The DAWN trial inferred the 
volume of penumbra from clinical assessment with the NIHSS.  Clinical deficit defined by 
NIHSS reflects the total volume of ischemic tissue since both infarct and penumbral tissue 
are functionally silent, therefore a large penumbra volume is implied in patients with severe 
clinical deficits but only a small infarct core volume.  Patients younger than 80 years were 
eligible if infarct volume < 31mL and NIHSS ≥ 10, or if 31mL ≤ infarct volume < 51mL 
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and NIHSS ≥ 20; patients 80 years or older were eligible if infarct volume < 21mL and 
NIHSS ≥ 10123.   
1.3 Medical Imaging in Ischemic Stroke 
 Medical imaging has become an important part of routine clinical care for AIS.  
Structural and functional information from admission neuroimaging is used to inform three 
key factors for triaging and management of patients with AIS symptoms: 1) is the stroke 
ischemic or hemorrhagic?  2) is there an intravascular occlusion?  3) is there viable 
penumbra tissue?  NCCT or MRI must be performed at admission to determine if the stroke 
is ischemic or hemorrhagic before initiating treatment, since treatment options for AIS can 
be detrimental to patients with primary ICH124.  CTA or magnetic resonance angiography 
(MRA) is also required to define the presence and location of LVO and to assess ease of 
access in patients being considered for IAT, and many centers now also routinely use CTP 
or PWI to guide treatment decisions.  In addition to improving acute diagnosis and 
providing personalized triaging based on tissue status instead of time from onset, 
physiological information from functional CT, MRI, and positron emission tomography 
(PET) has shaped AIS treatment strategies by advanced our understanding of stroke 
pathophysiology and tissue viability. 
1.3.1 Positron Emission Tomography 
 PET imaging relies on detection of coincident gamma rays produced in positron 
annihilation events to measure the spatial distribution of biological molecules radioactively 
labelled with positron emitting nuclides, known as radiotracers.  PET is a highly sensitive 
imaging modality, capable of detecting nanomolar concentrations of radiotracer, which can 
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assess a wide range of hemodynamic, functional, and metabolic parameters depending on 
properties of the radiotracer used.  A static PET scan performed sometime after radiotracer 
administration can measure the spatial distribution of radioactivity in the body relative to 
the total injected amount and body weight. On the other hand,  dynamic scanning used in 
conjunction with arterial blood sampling to quantify arterial delivery (arterial input 
function or AIF) of the radiotracer can allow more detailed pharmacokinetic modelling to 
be performed125. 
 PET imaging with 15O-labelled water and oxygen gas allows quantification of CBF, 
cerebral metabolic rate of oxygen (CMRO2), and oxygen extraction fraction (OEF) 
(fraction of oxygen extracted from the blood).  Contemporaneous assessment of blood flow 
and oxygen metabolism with PET imaging greatly advanced the understanding of the time-
dependence of tissue viability in ischemic stroke patients126,127.  Tissue with decreased CBF 
(CBF < 12 mL∙min-1∙100g-1) and CMRO2 usually progressed to infarction, while 
penumbral tissue had CBF between 12-22 mL∙min-1∙100g-1, elevated OEF, and preserved 
CMRO2 in the acute phase
128.  The coupled decrease in CBF and increase in OEF (termed 
‘misery perfusion’)129 was representative of still-viable tissue, that would eventually 
progress to infarction without reperfusion due to mismatch between metabolic demand and 
decreased oxygen delivery from CBF.  Animal studies of reversible focal cerebral ischemia 
showed that brain tissue with acutely elevated OEF progressed to infarction in animals with 
permanent MCA occlusion, but not in animals where the occlusion was reversed after 6 
hours, establishing the time-dependence of penumbral viability130,131.  Although tissue 
compartments in AIS are well defined by CBF, CMRO2, and OEF, there are drawbacks to 
using these parameters: a PET scanner and on-site cyclotron are required since the half-life 
19 
 
of 15O is only ~2 minutes132, and the rapid arterial blood sampling required for 
quantification is invasive. 
 More recently, tracers labelled with 11C or 18F which bind to neuronal cell surface 
receptors have been developed.  The half-lives of 11C and 18F are ~20 minutes and 110 
minutes respectively132, making them easier to use than 15O logistically.  One example is 
11C-labelled flumazenil (FMZ), which is a selective, high-affinity ligand for the central 
benzodiazepine receptor of the GABA receptor complex133.  GABA receptor activity can 
be used as a marker of neuronal integrity since GABA receptors are sensitive to ischemic 
damage134.  Clinical studies have shown that neocortex with decreased uptake of 11C-FMZ 
in the acute phase of stroke is infarcted134–136.  Fluoroethylflumazenil (FFMZ), a 
fluorinated analog of FMZ, works similarly for mapping GABA receptor activity137, and 
can be labelled with 18F, which is advantageous because the half-life is longer than 11C 138.  
The density of GABA receptors is low in the basal ganglia and negligible in white matter139, 
meaning FMZ, FFMZ and other benzodiazepine receptor ligands are not suitable for 
detecting infarction outside of cortical grey matter133.  Fluoromisonidazole (FMISO) 
radiolabelled with 18F is a hypoxia tracer which has been proposed as a marker of 
penumbral tissue.  FMISO accumulates in ischemic tissue by binding to macromolecules 
after being reduced by nitroreductases140.  Studies in a rat MCA occlusion model of AIS 
showed a pattern of FMISO uptake throughout the entire MCA territory at early time points 
30 to 60 minutes post occlusion, that evolved into a small rim of uptake surrounding the 
infarct core, and by 24 to 48 hours post occlusion there was minimal uptake in the final 
infarct141,142.  A similar time-dependent uptake pattern was also observed in human patients 
with AIS due to MCA occlusion143.  However, more recent studies using the same rat model 
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of AIS found that FMISO was retained in ischemic tissue for up to 6 hours post occlusion, 
consequently penumbral tissue which had already progressed to infarction within 6 hours 
still had elevated FMISO uptakes144.  Subsequent study showed strong FMISO uptake 
throughout the MCA territory even when administered up to 6 hours post occlusion, when 
most ischemic tissue had likely progressed to infarction.  Approximately 50% of the 
FMISO-retaining lesion was infarcted on histology, and most of the salvaged tissue in the 
lesion had signs of neuronal damage145.  These findings suggest increased FMISO uptake 
may not be a specific marker of penumbral tissue, further study is required to determine 
the applications of this radiotracer in AIS research. 
 Although the clinical utility of PET in AIS is limited due to cost and logistical 
complexity, it is still an invaluable tool for studying pathophysiological processes of AIS 
and serves as a gold standard for validating other imaging techniques used in AIS. 
1.3.2 Magnetic Resonance Imaging 
 MRI is a versatile imaging technique used for AIS diagnosis and prognosis, that 
can provide both structural and functional information depending on the pulse sequence 
used to create the image.  Acute ICH can be seen on MRI with gradient recalled echo 
(GRE) pulse sequences as a core of heterogenous signal intensity surrounded by a rim of 
hypointensity.  Studies have shown that NCCT and MRI with GRE pulse sequences are 
equivalent for ruling out ICH in patients being considered for IV t-PA124.  Thrombus 
location and length can also be assessed on susceptibility-weighted imaging (SWI) with 
GRE sequences, where the thrombus appears as a hypointense blooming artifact due to 
paramagnetic properties of deoxyhemoglobin contained in the clot146.  SWI has a high 
sensitivity (81% to 86%) and specificity (90%) for detecting clots in the anterior cerebral 
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circulation146,147, can reliably measure the length of clots longer than 6mm147, and clot 
composition can even be inferred since SWI is related to the red blood cell content of the 
clot148. 
 MRA can be performed either by injecting gadolinium-based contrast agent, or with 
non-contrast methods like the time-of-flight (TOF) technique, where flowing blood has 
hyperintense signal relative to surrounding static tissue.  Both contrast-enhanced and non-
contrast enhanced MRA can assess vessel patency in AIS149 and both methods have 
advantages and disadvantages.  TOF-MRA can be performed when contrast administration 
is not possible, but compared to contrast-enhanced MRA, the acquisition time is longer, 
making patient motion problematic, and the field of view (FOV) is smaller, so extracranial 
arteries cannot be imaged149.   
 DWI and associated apparent diffusion coefficient (ADC) maps are the clinical gold 
standard for detecting early ischemic damage.  One of the final steps towards irreversible 
tissue damage is cytotoxic edema, where water shifts to the intracellular space due to the 
increase in intracellular sodium and calcium after membrane ion pump failure.  DWI is 
sensitive to Brownian motion of water molecules and detects cytotoxic edema as a 
hyperintense lesion due to restricted diffusion of water molecules in the intracellular 
space150.  Contrast in DWI is due to differences in ADC as well as T2-weighted contrast, 
commonly referred to as ‘T2 shine-through’151.  To remove the effects of T2 shine-through, 
ADC maps are generated where cytotoxic edema is seen as a hypointense lesion with 
decreased ADC values151.  Acute DWI lesions are highly sensitive and specific markers of 
AIS152 and provide reliable estimates of the size and location of the final infarct core 
measured on follow-up imaging136,153.  Lesion reversal may occur in ~10% of patients, 
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where a small part of the acute lesion may appear normal on follow-up imaging,153 however 
the reversal is often transient and unlikely to represent salvaged tissue154. 
 Imaging of the infarct core with DWI can be complemented with PWI performed 
using IV administration of exogenous gadolinium-based contrast agent.  PWI with 
exogenous contrast agents can be broadly divided into dynamic contrast-enhanced (DCE)-
MRI, which relies on the T1 effects of gadolinium, or dynamic susceptibility contrast 
(DSC)-MRI, which relies on the susceptibility effect of gadolinium.  Signal enhancement 
versus time curves are measured by T1-weighted or T2/T2*-weighted echo-planar imaging 
and summary parameters like time-to-peak (TTP) and area-under curve (AUC) can be 
determined in a model-free approach155.  Or quantitative maps of CBF, Tmax, and other 
parameters can be computed with pharmacokinetic modelling if the measured signal 
enhancement curves are converted to contrast concentration versus time curves, and an AIF 
is available.  Measured signal enhancement is not linearly related to contrast concentration 
in PWI, making absolute quantitation of hemodynamic parameters more difficult.  Contrast 
concentration can be calculated from signal enhancement using pulse sequence-dependent 
equations155, DCE-MRI requires pre-contrast T1 mapping in addition to pulse sequence-
dependent equations to calculate the contrast concentration versus time from the measured 
signal156.  Accurately measuring the AIF can also be problematic because of in-flow/out-
flow effects (blood flowing into or out of the imaging volume causing signal increases and 
decreases respectively), limited temporal resolution and other factors156.  When an AIF of 
sufficient quality cannot be derived from the PWI scan, alternatives such as population-
averaged AIFs may be used instead156, but this can lead to errors in parameter calculation 
if the chosen population-averaged AIF is not representative of the individual patient. 
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 Studies have shown that the deconvolution-based Tmax parameter is optimal for 
identifying penumbra (Tmax > 6s) on admission DSC-MRI
157,158.  Model-free summary 
parameters do not account for arterial delivery and are therefore affected by factors like 
bolus dispersion and cardiac output159, but studies show TTP is highly correlated with Tmax 
and performs similarly for predicting penumbra volume160,161.    DWI/PWI mismatch is a 
widely used neuroimaging paradigm for managing AIS patients based on infarct and 
penumbra volumes measured from admission DWI and PWI using fully automated post-
processing software (RApid processing of PerfusIon and Diffusion, or RAPID)162.  
DEFUSE 3 recently used RAPID to show that patients with LVO and mismatch on 
admission DWI/PWI or CTP (infarct volume < 70mL, infarct/penumbra ratio > 1.8, and 
penumbra volume > 15mL) can still benefit from IAT up to 16 hours post symptom 
onset122.  PWI can also be performed with endogenous contrast using arterial spin labelling 
(ASL), where magnetically-labelled, arterial blood acts as an endogenous tracer rather than 
administering exogenous gadolinium-based contrast.  However, ASL is not commonly 
used for AIS because relaxation of the magnetic label during prolonged transit times caused 
by ischemia can lead to poor signal-to-noise ratio and underestimated CBF163. 
 Another MRI-based paradigm for AIS patient management is mismatch between 
admission fluid-attenuated inversion recovery (FLAIR) and DWI.  Hyperintense lesions 
on FLAIR are highly sensitive markers of infarct core164 but are generally not visible in the 
first 3 hours post onset, whereas DWI lesions are visible 1 hour or less post onset165.  
Studies have shown that FLAIR-DWI mismatch (hyperintense DWI lesion with no FLAIR 
lesion) is a surrogate marker of ischemia duration166 that can identify patients with time 
from symptom onset < 4.5 hours with high specificity167.  A recent randomized, placebo-
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controlled trial found that treating patients with FLAIR-DWI mismatch and unknown 
stroke onset time with IV t-PA improved functional outcome despite increased risk of 
symptomatic ICH168.  FLAIR-DWI mismatch could potentially be used in patients with 
unknown onset times (approximately 14 to 25% of all AIS patients)169,170 to identify those 
with ischemia duration < 4.5 hours, who are more likely to benefit from thrombolysis. 
 In addition to providing anatomical and functional information about vessel 
patency, tissue viability, ischemia duration and other factors, MRI is more readily available 
in the AIS setting than PET and does not require ionizing radiation.  However, MR scanners 
have limited availability compared to CT outside of large city hospitals or academic 
centers, and patients with MRI contraindications (e.g. claustrophobia, ferromagnetic 
implants, pacemakers) must be excluded from imaging; screening for contraindications 
also results in longer door-to-needle times compared to CT171.  Despite these limitations, 
MRI is an important modality for triaging and management of AIS patients. 
1.3.3 Computed Tomography 
 CT is the most commonly used modality for assessing AIS patients because it is 
more widely available172, less expensive, and faster compared to MRI, and CT can be 
performed without first screening the patient for common MRI contraindications.  Patients 
with AIS symptoms are often assessed with NCCT, CTA or multiphase CTA, and CTP. 
1.3.3.1 Non-Contrast Computed Tomography 
 Admission NCCT is required for any patient with stroke symptoms to rule out non-
vascular stroke mimics and primary ICH.  The intensity in each voxel of CT images, 
expressed in Hounsfield Units (HU), is linearly proportional to the x-ray linear attenuation 
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coefficient.  NCCT has good sensitivity for detecting acute phase ICH which appears as a 
hyperintense lesion124, and is more cost-effective as a screening tool than MRI74.  In 
addition to ruling out ICH, careful examination of NCCT can also yield information about 
early ischemic damage and clot characteristics.  ASPECTS is a standardized CT reading 
method based on assessment of 10 regions of interest (ROI) located in the MCA territory 
visible in two 5mm thick CT slices, one at the level of the thalamus and basal ganglia, and 
one just rostral to ganglionic structures.  One point is subtracted from 10 for each ROI with 
evidence of early ischemic damage118.  Signs of early ischemic damage visible on NCCT 
include hypoattenuation, sulcal effacement due to mass effect from edema, and loss of 
gray-white matter differentiation, including loss of the insular ribbon and obscuration of 
the lentiform nucleus173.  ASPECTS ≤ 7 has been associated with increased risk of poor 
functional outcome and symptomatic ICH in patients treated with IV t-PA118.  
Retrospective studies of patients in the NINDS and ECASS II trials found no significant 
effect of baseline ASPECTS on IV t-PA treatment effect174,175, however ASPECTS ≤ 7 
was associated with significantly increased risk of symptomatic ICH in the ECASS II 
patients175, and there was a trend toward decreased treatment benefit and increased 
mortality in the NINDS patients174.  Low ASPECTS was also associated with increased 
risk of poor functional outcome, mortality, and symptomatic ICH in patients treated with 
IAT176 and was part of the exclusion criteria for three of the seminal trials demonstrating 
the efficacy of IAT113,114,117.  Current clinical guidelines suggest IAT should only be 
performed in patients with ASPECTS ≥ 658, but there is some evidence that patients with 
ASPECTS ≤ 5 still benefit from IAT177,178. 
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 Intraluminal thrombus in the distal ICA, M1, and M2 segments of the MCA can 
also be visualized in patients as hyperintensity on NCCT, this has been proposed as a 
method of confirming the presence of LVO without performing CTA in patients being 
considered for IAT.  The hyperdense artery sign can detect LVO (as assessed with gold 
standard CTA) with high specificity (95-100%) and moderate sensitivity (30-55%) when 
NCCT is reconstructed with standard 5mm thick slices179,180, studies have shown that 
sensitivity can be improved to 70-100% by using thinner (0.625-1.5mm) slices180–182.  
Thrombus length measured on NCCT also agrees with length measured on CTA within 
±1mm when slice thickness is ≤ 2.5mm183.  Studies have shown that IV t-PA is less 
effective for thrombi longer than 10mm on NCCT184, and that clot length and location are 
associated with outcome in IAT-treated patients185.   
1.3.3.2 Computed Tomography Angiography 
 CTA requires IV administration of iodinated contrast agent and rapid scanning after 
a short delay to capture peak intravascular enhancement.  Iodinated k-edge falls within the 
energy range of diagnostic x-rays, causing iodinated contrast agents to produce a 
measurable increase in x-ray attenuation (~30HU per 1mg/mL of iodine), and therefore 
signal intensity measured on CT.  CTA source images can be viewed directly, or as 
maximum intensity projections or 3D reconstructions with postprocessing; blood vessels 
perfused with contrast agent as the image is acquired will appear hyperdense.  Evaluation 
of flow dynamics is also possible with 4D-CTA or multiphase CTA, where images are 
acquired either continuously (4D-CTA), or at multiple discrete time points (multiphase 
CTA) as contrast travels through cerebral vasculature, rather than conventional CTA where 
imaging at a single time point is performed.  CTA has better spatial resolution (~0.5mm 
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isotropic resolution)186 than MRA and is less invasive and faster than digital subtraction 
angiography (DSA), the gold standard for cerebral angiography, while also providing near 
equivalent evaluation of the presence and location of occlusions187,188. 
 The presence, and location of occlusions on angiography are important prognostic 
factors that have implications for patient triaging and management.  Current clinical 
guidelines require LVO to be confirmed on angiography before initiating IAT58.  Failure 
to perform admission CTA was one major limitation of earlier IAT trials, resulting in many 
enrolled patients having no evidence of occlusion, or occlusions not accessible by IAT 
upon arrival to the angiography suite110,111.  All trials showing benefit of IAT to date have 
used CTA or MRA to confirm the presence and location of LVO.  Presence, length and 
location of the clot on CTA is also a predictor of recanalization in IV t-PA treated patients.  
The benefit of IV t-PA may be diminished in up to ~25% of AIS patients who have no 
visible occlusion on CTA189; in patients with visible occlusions, lower recanalization rates 
are observed for proximal occlusions95,190, and clots longer than 15mm191.  These and other 
clot characteristics evaluated on CTA, such as absence of residual flow through the clot192, 
can help identify patients who are more likely to benefit from IAT rather than IV t-PA.  
The overall extent of anterior circulation clots can also be assessed on CTA using a semi-
quantitative scale called the clot burden score.  Points are subtracted from 10 for absence 
of contrast opacification across the full cross-section of any parts of the intracranial ICA, 
proximal, or distal M1 segment of the MCA (2 points each), M2 segments of the MCA, 
A1 segment of the ACA, and extracranial ICA (1 point each)193.  High clot burden scores 
have reasonable sensitivity and specificity (73% and 65% respectively) for predicting good 
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functional outcome in patients treated with IV t-PA194 and have been associated with 
smaller final infarct volume and improved functional outcome in IAT-treated patients195. 
 Another important aspect of CTA is evaluation of collateral circulation, which 
provides alternative routes for blood to reach tissue when a proximal cerebral artery is 
occluded.  Cerebral collateral circulation consists of the Circle of Willis, which links the 
anterior and posterior circulation, connections between external carotid artery branches and 
branches of the ICA, and leptomeningeal collaterals which connect territories of the MCA, 
ACA, and posterior cerebral artery196.  More extensive collateral circulation implies more 
preserved CBF in the affected vascular territory, and therefore slower progression of 
ischemic penumbra to infarction.  Studies have confirmed that more extensive collateral 
circulation observed on angiography were associated with smaller final infarct volumes 
and better functional outcomes in AIS patients197,198.  There are numerous semi-
quantitative 3- or 5-point scales for grading collateral circulation on CTA by assessing the 
degree of collateral vessel opacification in the affected vascular territory relative to the 
contralateral side199–202.  The regional leptomeningeal collateral (rLMC) score differs by 
scoring the collateral circulation relative to the contralateral side in the predefined regions 
used in ASPECTS203.  Since conventional CTA represents only a single time point, delayed 
collateral vessel opacification can be missed depending on bolus characteristics and the 
timing of the scan.  Dynamic CTA techniques, such as 4D-CTA or multiphase CTA, 
provide time resolved data which is less dependent on scan timing or bolus characteristics.  
Collateral scoring on dynamic CTA assesses the extent and prominence of collateral vessel, 
as well as the time delay for retrograde contrast filling relative to the contralateral side204.  
Multiple studies have found collateral evaluation on dynamic CTA to better predict 
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functional outcome compared to conventional single-phase CTA119,205,206, likely due to less 
instances of underestimated collateral score due to delayed enhancement missed on single-
phase CTA207.  Collateral scores from multiphase CTA were used to select patients for IAT 
within 6 hours of symptom onset in the ESCAPE trial114. 
1.3.3.3 Computed Tomography Perfusion 
 In the last decade CTP has become more common upon admission of patients with 
AIS symptoms.  Similar to perfusion-weighted MRI, CTP involves repeated CT scanning 
of the brain as an IV bolus injection of iodinated contrast agent is administered and 
transient changes in signal intensity versus time (time-density curves or TDC) are 
measured in each tissue voxel as contrast passes through brain vasculature.  Signal 
enhancement measured in each voxel by CTP is linearly proportional to the concentration 
of iodinated contrast agent in the tissue, so difficulties converting measured signal 
enhancement to tissue and arterial contrast concentration versus time curves (Q(t) and Ca(t) 
respectively) encountered in perfusion-weighted MRI due to contrast non-linearity are 
avoided208.  CTP also has faster sampling rates and is not affected by in-flow/out-flow 
effects seen in perfusion-weighted MRI, allowing the AIF to be measured from the CTP 
acquisition rather than relying on population-averaged AIFs and other alternatives used in 
PWI. 
1.3.3.3.1 Calculation of Hemodynamic Parameters 
 Hemodynamic parameters can be calculated using deconvolution or non-
deconvolution models.  Generally, non-deconvolution models are faster but rely on 
simplifying assumptions about brain hemodynamics which do not always hold true, 
whereas deconvolution models are more physiologically appropriate but require advanced 
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algorithms that extend computation time208.  The work in this thesis only uses 
deconvolution models.  The tissue TDC measured in each voxel during the CTP acquisition 
is dependent on the arterial TDC (Ca(t)), and the inherent hemodynamic properties of the 
tissue208.  Under ideal injection conditions, where a unit bolus of contrast is deposited in a 
feeding artery immediately upstream from the tissue of interest (i.e. Ca(t) is a delta function 
of unit height), Q(t) in each voxel would depend only on the hemodynamic properties of 
the tissue.  The theoretical Q(t) corresponding to an ‘impulse’ arterial input is called the 
impulse residue function (IRF or R(t)) and can be thought of as the fraction of contrast 
remaining in the tissue over time following a unit bolus of contrast.  Clinical replication of 
these injection conditions is not practical, so the AIF is measured from a proximal cerebral 
artery and assumed to represent the arterial input to all of the tissue of interest208.  Since 
the amount of contrast delivered to the tissue at any instant is 𝐹 ∙ 𝐶𝑎(𝑡), any general Q(t) 
can be represented as the sum of time-shifted IRFs scaled by F·Ca(t) at each time point
209 
(Figure 1.1): 
𝑄(𝑡) = 𝐹 ∙ ∫ 𝐶𝑎(𝑡′) ∙ 𝑅(𝑡 − 𝑡
′) ∙ 𝑑𝑡′
𝑡
0
 
 Where t is the total scan time.  The integral term is the convolution of the arterial 
TDC and the IRF.  This can be rewritten as the following by multiplying F into R(t) (flow-
scaled IRF or RF(t))
210: 
𝑄(𝑡) = 𝐹 ∙ 𝐶𝑎(𝑡) ⊗ 𝑅(𝑡) = 𝐶𝑎(𝑡) ⊗ 𝑅𝐹(𝑡) 
Where ⊗ is the convolution operator (Figure 1.2).   
31 
 
Figure 1.1: The concept of deconvolution applied to CT Perfusion 
 
Fig. 1.1: This figure was adapted from ‘Functional CT: Physiological models’, by Ting-
Yim Lee published in Trends in Biotechnology (2002; 20(8): 3-10)210.  The left and right 
columns show arterial TDCs and the corresponding tissue TDCs.  The top row illustrates 
the concept of time invariance; if hemodynamic conditions are constant over the duration 
of the CTP acquisition, then two impulse arterial inputs of equal height occurring at 
different times result in two identical IRFs, shifted in time.  The middle row illustrates the 
concept of linearity; if enhancement measured by the CT scanner is linearly related to the 
concentration of contrast agent, then the height of the IRF will be linearly related to the 
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arterial enhancement multiplied by the flow (F) delivery.  Under these conditions, any 
general AIF can be represented as a series of delta functions with heights given by the 
measured arterial contrast concentration versus time curve, and any tissue TDC can be 
represented as a series of time-shifted IRFs scaled by the measured arterial contrast 
concentration versus time curve. 
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Figure 1.2: Graphical representation of CTP deconvolution equation 
 
Fig. 1.2: Graphical representation of the operational equation of CTP.  Q(t) measured in 
each voxel of brain tissue is a combination of the arterial delivery of contrast (represented 
by AIF(t)) and the inherent hemodynamics of that voxel of brain tissue (described by 
RF(t)), therefore Q(t) is a convolution of the AIF and RF(t).   
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 Deconvolution algorithms solve for RF(t) in each tissue pixel to approximate the 
regional tissue hemodynamics that would be measured under ideal injection conditions by 
removing the effect of Ca(t).  The shape of RF(t) depends on the model used in the CTP 
software, all work contained in this thesis uses a form based on the Johnson-Wilson 
model211.  The Johnson-Wilson model allows CBF, CBV, MTT, contrast arrival time (T0), 
and Tmax (Figure 1.3).  
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Figure 1.3: Sample IRF 
 
Fig. 1.3: An example of the flow-scaled IRF from the Johnson and Wilson model.  The 
delay between contrast arrival at the AIF and the tissue TDC is the arrival time (T0), the 
height of the initial box-shaped portion is equal to CBF, and the area under the IRF is equal 
to CBV.  The width of box (w) is the minimum transit time through the tissue, and E 
describes the fraction of contrast with transit time equal to w.  The remaining fraction of 
contrast (1 – E) with transit times longer than w is described by the tail portion, which is 
assumed to be an exponential decay function with rate constant k.  MTT is calculated as 
CBV divided by CBF, as required by the central volume principle, and Tmax is calculated 
as T0 plus half of the MTT (T0 + MTT/2)
210. 
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1.3.3.3.2 Technical Considerations for CTP Acquisition 
 Current commercially available CTP software packages are almost fully automated, 
the only user input is reviewing the AIF and venous output function (VOF) automatically 
selected by the program, or manually selecting them if the software does not have 
automated post-processing features.  The AIF is usually measured from a large cerebral 
artery that is orthogonal to the image plane to minimize partial volume averaging.  
Depending on the brain region covered by the scan, the intracranial ICA, or ACA are 
commonly used for the AIF, and the VOF is usually taken from the posterior superior 
sagittal sinus212.  Underestimation of the AIF due to partial volume averaging can be 
corrected by normalizing the area under the AIF to that of the VOF210. 
 CTP was previously restricted by limited z-axis coverage, but modern 256/320-row 
multidetector CT scanners can cover 16cm in the z-axis direction, allowing nearly the 
whole brain to be imaged in a single scan212.  Scan coverage can be increased further using 
table-toggling techniques, where the table is moved back and forth so that two adjacent 
slabs are imaged during the same bolus injection212.  One limitation of CTP is the ionizing 
radiation dose to the patient, which depends not only on x-ray tube voltage and current, but 
also the duration of the scan, the temporal sampling interval, and other factors.  CTP scan 
duration varies from 40-60s when only perfusion is necessary, up to 90-180s when both 
perfusion and BBB permeability are assessed.  Radiation dose increases as sampling 
interval shortens, so longer scans are divided into multiple phases with progressively longer 
sampling intervals to reduce radiation dose to the patient.  Multiphase scans generally 
consist of a 30-45s arterial phase with a sampling interval of 1 image per second, then a 
30-45s venous phase with a sampling interval of 1 image per 2-3s, and finally a 90-120s 
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delayed phase with a sampling interval of 1 image per 15s, to limit radiation dose213.  When 
table-toggling is used to increase z-axis coverage the sampling interval must be decreased 
to 1 image every 2-3s to accommodate table motion.  Radiation dose can be decreased by 
shortening the scan duration, but if the scan is too short to capture the delayed contrast 
washout from ischemic tissue it can lead to errors in quantitative values.  Previous studies 
have found that shortening the duration of perfusion scans to 40-50s results in 
underestimated CBV, MTT and Tmax values in AIS patients, and by extension, under- and 
overestimated infarct/penumbra volumes derived by Tmax and CBV thresholds 
respectively214–217.  Further study is required to determine optimal CTP scan duration for 
AIS applications that can minimize the radiation dose to the patient without affecting 
quantitative results.  Increasing the sampling interval in the first phase of the scan can also 
decrease the dose, but can lead to errors in quantitative perfusion results, particularly for 
sampling intervals longer than 1 image every 3s.  Studies have found quantitative perfusion 
results may be over- or underestimated at sampling intervals ≥ 3s 218,219, but qualitative 
lesion appearance, diameter, and volume218,219, and ASPECTS applied to CTP maps are 
relatively unaffected219.  Tube voltage of 80kVp is recommended for brain CTP since this 
results in mean x-ray energy closer to the iodine k-edge, improving iodine detection 
sensitivity, while also decreasing radiation dose compared to higher tube voltage 
settings220.  Tube current of 100-200mA is recommended for brain CTP but decreasing 
tube current to 50mA may reduce effective dose by ~50% without significantly affecting 
quantitative perfusion values221.  Alternative image reconstruction techniques, such as 
adaptive statistical iterative reconstruction, can also be used to lower radiation dose without 
impacting image quality222, or improve quality of CTP maps without increasing radiation 
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dose223.  A standard 2-phase CTP study for assessing perfusion and BBB permeability has 
an effective dose of ~5mSv224.  It is commonly assumed that an effective dose of 1Sv will 
increase the risk of dying from cancer by 5%225; extrapolating this to a dose of 5mSv means 
that a brain CTP study increases the risk of cancer mortality by ~0.025%. 
1.3.3.3.3 Applications for Ischemic Stroke 
 The main application of CT Perfusion in AIS is estimating the volume of 
irreversibly damaged infarct core and/or salvageable penumbra by applying thresholds to 
hemodynamic parameter maps.  CTP-derived infarct and penumbra volumes may be 
underestimated for z-axis coverage ≤ 8 and 4cm respectively, compared to what would be 
measured with 16cm coverage226.  Nevertheless, even with 4cm coverage, studies have 
found infarct volumes quantified on admission CTP were better correlated with final infarct 
volume227 and more predictive of functional outcome than ASPECTS assessed on 
NCCT228,229 and CTP maps, as well as collateral score and clot burden score assessed on 
CTA229.  Standardization of thresholds used to define infarct and penumbra has been 
problematic.  Studies show infarct volumes derived using different thresholds are 
significantly different230, and that even the same threshold applied to maps computed using 
different software will produce different infarct volumes because of differences in the 
deconvolution algorithm used by each software231.  Based on results from DEFUSE 3 and 
DAWN, current clinical guidelines recommend CTP with postprocessing by the RAPID 
software package to determine eligibility for IAT in AIS patients with LVO and either 
unknown symptom duration, or symptom duration between 6-24h58.  Patients are selected 
for IAT based on mismatch between infarct (CBF ≤ 30% of the contralateral side) and 
penumbra (Tmax > 6s) volumes
122, or mismatch between infarct volume and severity of 
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clinical deficit as assessed by NIHSS123 (both mismatch paradigms are described in detail 
in the Mechanical Thrombectomy section above). 
 Assessing permeability-surface area product (PS) of the blood-brain barrier with 
CTP can also be used to predict the risk of hemorrhagic transformation following 
revascularization therapy.  Both the average PS within the ischemic territory and the 
volume of tissue with elevated PS can predict hemorrhagic transformation with good 
specificity (83-94%) and moderate sensitivity (51-77%)232,233.  In the future PS maps from 
CTP could be useful for identifying patients with an increased risk of hemorrhagic 
transformation, where use of thrombolytic agents may be contraindicated.  CTP performed 
after treatment also has the potential to provide additional prognostic information beyond 
what is available with angiographical imaging.  Approximately ~15% of IAT-treated 
patients from clinical trials had near-complete or complete reperfusion on follow-up DSA 
(as assessed by the semi-quantitative modified thrombolysis in cerebral infarction scale, or 
mTICI scale) but still went on to have poor functional outcomes113,114,116,117,234.  
Reperfusion assessed on follow-up CTP was a better predictor of outcome in AIS patients 
treated with IV t-PA than recanalization of the occluded vessel on follow-up CTA235.  
Follow-up CTP may also be a better predictor of functional outcome in IAT-treated patients 
than applying the mTICI scale to post-procedural DSA.  As further advances are made in 
neuroprotective drugs and therapies, assessment of reperfusion following treatment of AIS 
may become important for identifying patients most likely to benefit from additional 
therapy.    
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1.4 Animal Models of Ischemic Stroke 
 Animal models of focal cerebral ischemia have been developed to further our 
understanding of stroke pathophysiology and develop treatment strategies and novel 
imaging techniques in a controlled environment.  Animal models remove the impact of 
confounding factors commonly found in the clinical setting (e.g. diabetes, vascular 
cognitive impairment, previous stroke, etc.) and provide precise control over variables like 
ischemia duration, something that is impossible to control in a clinical setting.  
Additionally, radiation dose is less of a concern in animal models than in patients, so 
multimodal CT or PET imaging can be performed at several time points with less concern 
for the cumulative radiation dose.  Although animal models present many advantages over 
clinical studies, it should be noted that no animal model completely replicates the complex 
processes of ischemic stroke in humans, often making translation of results from animal 
studies to the clinical setting challenging. 
 Most models of focal cerebral ischemia rely on occlusion of the MCA with an intra-
arterial approach.  The intraluminal suture procedure involves advancing a filament of 
surgical suture through the ICA to block the MCA; this model can be used to replicate 
permanent occlusion or transient occlusion by removing the suture after a predefined 
time236.  Mechanical abrasion from the filament can result in increased risk of endothelial 
damage or hemorrhage, but when implemented properly this procedure creates infarcts that 
increase in volume over time and are highly reproducible between animals.  Another option 
is IA injection of either microspheres or autologous blood clots into the ICA, causing 
occlusion of the MCA.  Using the embolic model with an autologous blood clot is the only 
model suitable for studying thrombolytic agents237, but infarct size is also more variable 
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due to variability of endogenous fibrinolysis between animals.  Other models require a 
craniectomy to expose, and then occlude the MCA using electrocoagulation, clips, or 
ligatures238, or by applying the vasoconstrictor endothelin-1 (ET-1) onto the exposed 
MCA239.  ET-1 can also be injected into the MCA territory to cause vasoconstriction which 
eventually leads to infarction240. 
 Animal stroke studies are most commonly performed in mice and rats because they 
are reproducible and cost-effective.  However, rat brains are lissencephalic (smooth surface 
lacking gyri and sulci), and the proportion of white matter is much lower than in humans, 
limiting the applicability of results from these models to humans.  Therefore, stroke models 
have also been developed in larger animals such as dogs, pigs, and even primates, all of 
which have a gyrencephalic brain, and a proportion of gray and white matter more like 
humans.  The disadvantages of using larger animals are increased cost, ethical concerns, 
and differences in cerebrovascular anatomy.  Many large mammals used for biomedical 
research (e.g. pigs) have a rete mirabile in the extracranial portion of the internal carotid 
artery – a fine meshwork of blood vessels which reconstitutes into the internal carotid 
artery further downstream in the carotid canal241, making it impossible to employ the 
intraluminal suture, and embolic stroke models in these animals.  Most large animal stroke 
models require craniectomy of the orbital rim242, or enucleation of the eye243 so that the 
MCA can be exposed and occluded.  These complex surgical procedures make it difficult 
to maintain the animal at its basal physiological state throughout the duration of the 
experiment.  Animal models of stroke are an important way of testing new treatment 
techniques for AIS, a less invasive large animal stroke model could improve clinical 
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translation by making it easier to test new therapies in models that are more representative 
of human stroke.  
1.5 Future Diagnosis and Treatment of Stroke 
Treatment of AIS, and neuroimaging-based triaging and management of AIS 
patients have progressed rapidly in recent decades, but there are still subgroups of patients 
where the efficacy of existing treatments have not been confirmed.  For example, the 
benefit of IAT for treating distal MCA (M2 or M3 segment), ACA, and posterior cerebral 
circulation occlusions is not clear.  Meta-analyses of pooled data suggested treating distal 
occlusions of the MCA (M2 or M3 segments) with mechanical thrombectomy may be 
beneficial, but statistical significance was not found104,244,245.  Occlusion of the ACA and 
the posterior cerebral circulation are responsible for ~5%246 and 15-20%247 of AIS 
respectively.  There is some evidence that thrombectomy with stent retrievers improves the 
likelihood of recanalization and good outcome in patients with ACA occlusion246,248, and 
basilar artery occlusion249, but more study is needed to refine thrombectomy techniques 
and define appropriate inclusion criteria for treatment.  Because of the uncertain benefit of 
IAT for treating distal occlusions, these patients are currently treated with IV t-PA, but 
treatment with thrombolysis is restricted by the 4.5h time window, and inability to treat 
patients with unknown onset times.  A recent randomized, placebo-controlled trial showed 
that patients with unknown stroke onset times who have FLAIR-DWI mismatch benefit 
from IV t-PA168, but equivalent CT-based selection criteria should also be studied due to 
the greater availability of CT outside of major cities. 
Research into new thrombolytic drugs and neuroprotective techniques is also 
ongoing.  Alteplase is the only t-PA class drug approved by the FDA but there is some 
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evidence that IV administration of tenecteplase (TNK), another recombinant t-PA with 
higher fibrin specificity250 and a longer half-life, could result in greater reperfusion rates251 
and lower rates of ICH252.  TNK may have a role in routine care if the efficacy is shown to 
be equivalent to alteplase because it is less expensive and easier to administer (one bolus 
versus a bolus followed by 1h infusion of alteplase)252.  Trials comparing IV TNK and 
alteplase for AIS treatment within 4.5h of onset and treatment of minor stroke or transient 
ischemic attack within 12 hours of onset are ongoing. 
Neuroprotective drugs and therapies are also being studied as method to maximize 
penumbra salvage by slowing the progression of ischemic tissue toward infarction.  One 
prominent example is the neuroprotective drug NA-1, which acts on the postsynaptic 
scaffolding protein PSD-95 to inhibit glutamate excitotoxicity.  NA-1 reduced final infarct 
volume by ~40% in a non-human primate model of AIS253 and was also found to be safe 
and effective for reducing the number of DWI lesions in humans following endovascular 
brain aneurysm repair (a procedure where small embolic strokes are common)254.  A phase 
3 randomized, placebo-controlled trial is currently underway to determine the efficacy of 
NA-1 for improving functional outcomes in AIS patients treated with IAT.  Non-
pharmaceutical neuroprotective therapies are also under investigation, including selective 
brain cooling with intra-arterial infusion of cold saline255,256.  Previous research has shown 
that inducing hypothermia provides neuroprotective effects in the acute phase of stroke by 
reducing CMRO2 and excitotoxicity, and in the subacute phase by preserving BBB 
integrity257.  IA infusion of cold saline offers similar neuroprotective effects without the 
adverse effects associated with hypothermia, such as pneumonia or cardiac arrhythmia258.  
A recent study of cold saline infusion performed before and after IAT resulted in smaller 
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final infarct volume and a non-significant trend toward better functional outcomes255.  As 
neuroprotective drugs and therapies continue to be refined, imaging-based selection criteria 
will need to be studied to identify patients who will be most likely to benefit. 
1.6 Research Objectives 
The main objective of this work was to identify limitations and potential areas for 
improvement in current CTP-based methods for guiding AIS treatment and functional 
outcome prognostication following AIS.  The thesis is divided into the following parts: 
1) Developing a large animal AIS model for deriving CTP parameter thresholds for 
infarction after 3h of ischemia. 
2) Assessing the effect of scan duration on perfusion parameters calculated by CTP 
and determining optimal scan durations for infarction thresholds. 
3) Determining the association between reperfusion of previously ischemic tissue 
after IAT, as assessed by follow-up CTP, with good functional outcome in AIS 
patients. 
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Chapter 2  
2 Absolute Cerebral Blood Flow Infarction Threshold for 3-
hour Ischemia Time Determined with CT Perfusion and 
18F-FFMZ-PET Imaging in a Porcine Model of Cerebral 
Ischemia 
2.1 Introduction 
Both MRI and CT are highly sensitive for infarct core.  Generally, CT is used 
preferentially for stroke diagnosis/prognosis because of availability, cost and speed.  Along 
with NCCT and CTA, CTP is now consistently acquired at many institutes. CTP based 
time-dependent thresholds for infarct core have been recently derived using data from 
ischemic stroke patients1.  These thresholds will have important implications for patient 
triaging and will be useful in wake-up and late presenting strokes. Predicting the infarct 
core evolution could help identify patients who will benefit most from transfer to tertiary 
centers capable of IAT, the new standard of care.   
However, many threshold derivation studies used follow-up imaging performed 1-
7 days after symptom onset to define the infarct core2-8, introducing uncertainty caused by 
infarct expansion in the time between admission and follow-up imaging.  Furthermore, 
some of these studies used DWI to define the infarct core5,6,8.  DWI lesion reversal has 
been observed in both human and animal ischemic stroke9,10, though it should be noted that 
clinical instances of DWI lesion reversal are rare11 and should not deter anyone from using 
MRI if it is logistically feasible to acquire in the acute setting. 
One alternative, which may circumvent uncertainties caused by infarct expansion 
and DWI, is to use large animal stroke models to derive time-dependent thresholds for 
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infarction.  The logistical complexity of producing and using radiotracers in the clinical 
acute stroke setting are not a factor, and radiation dose is less of a concern in animal 
models, so the infarct can be defined using PET imaging with radiolabeled FMZ, or its 
fluorinated analog, FFMZ.  This gold standard method reliably predicts the final infarct 
and is less prone to false positives than DWI12.  Furthermore, animal models provide 
greater control over the time interval between symptom onset and tissue status 
determination, allowing infarction thresholds to be determined for many different ischemia 
durations.   
Porcine models are more useful then small animal models since the gyrencephalic 
brain is more similar to a human brain in terms of grey/white matter composition and size13.  
However, the rete mirabile makes it impossible to use intra-arterial catheter-based methods 
commonly used to initiate cerebral ischemia in small animal models14.  As a result, most 
porcine models of stroke rely on complex and invasive surgical procedures to access the 
middle cerebral artery, so a clip or ligature can be applied15,16.  Using ET-1 to cause 
transient cerebral ischemia does not require complicated surgical procedures and has been 
well established in rodents and lower primates17,18.  ET-1 binds to endothelin receptors type 
A and B in cerebral vascular smooth muscle cells, triggering a potent vasoconstriction that 
induces changes in CBF severe enough to induce infarction, with minimal tissue edema19.  
Recently, the ET-1 method was used in a porcine model of cerebral ischemia20.   
In this study, we presented an ET-1 based porcine model of cerebral ischemia for 
determining time dependent CBF thresholds for infarction using CTP and 18F-FFMZ-PET 
imaging, and we determined a CBF threshold for infarction after 3hrs of ischemia. 
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2.2 Methods 
2.2.1 Acute Cerebral Ischemia Model 
All animal experiments were conducted following the guidelines of the Canadian 
Council on Animal Care and approved by the Animal Use Subcommittee at the University 
of Western Ontario (Protocol #2007-050).  Duroc Cross Pigs were picked up from a nearby 
farm on the day of the experiment and were not housed at the laboratory prior to 
experiments.  Out of the 11 animals (average weight 26 ± 5 kg) used in this study, 7 were 
female and 4 were male.  Anesthesia was induced in the animals using 4-5% isoflurane.  
Anesthesia was maintained by mask with 3-4% isoflurane until intubation. Propofol (16-
22 mg/kg) was given IV for intubation.  The pig was ventilated (10-15 cc/stroke volume, 
20-30 breath per minute) with 2.5-3.5% isoflurane with oxygen and medical air (2:1 
medical air to oxygen ratio) for the duration of the experiment.  A 22G cephalic vein 
catheter was placed for injection of CT contrast (Isovue 370) and 18F-FFMZ. One femoral 
artery was cannulated with a catheter for measuring blood pressure, blood gases (pO2 and 
pCO2), glucose and pH throughout the experiment. In addition, heart rate, arterial oxygen 
saturation, end-tidal carbon dioxide tension (CO2), respiration rate and blood pressure were 
continuously monitored (Surgivet).  The animal was wrapped in a circulating hot water 
blanket and rectal temp were monitored continuously throughout the experiment.   
A CT scan was done to identify sixteen contiguous 2.5mm thick slices which 
included the largest coronal sections of the brain, then a baseline CTP study was performed 
using the procedures outlined in the next section.  A target slice location showing the 
maximal extent of the MCA territory was selected following the baseline CTP scan.  This 
target slice was marked on the pig’s head using the CT scanner laser positioning light, the 
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scalp was incised (silver nitrate sticks used to control bleeding) and a 1-2mm diameter burr 
hole was made with a Dremel hand tool through the skull.  A 27G 1 ¼” long needle attached 
to a 1mL saline syringe with PE 40 tubing was preloaded with ET-1 and inserted through 
the burr hole into the brain.  An axial CT scan was then acquired to verify that the needle 
tip is within the cerebral cortex in the target slice.  33µg of ET-1 in 150µL of sterile water 
was injected at 50 µL/min using an infusion pump.  CT Perfusion studies were performed 
10 and 30min after the ET-1 injection, and then every 30min for the remainder of the 3hr 
monitoring period. 
Animals were under anesthetic for the entire study to reduce unnecessary animal 
suffering.  If anything seriously detrimental had happened during surgery or scanning, the 
animal would have been euthanized immediately by intravenous potassium chloride 
overdose under full deep anesthetic, however there were no serious incidents so early 
termination of experiments was not necessary.  At the conclusion of the experiment animals 
were euthanized by intravenous potassium chloride overdose under full deep isoflurane 
anesthetic.   
2.2.2 On-line CBF Monitoring with CT Perfusion 
CTP studies were acquired on the GE Healthcare Discovery VCT PET/CT scanner 
using the following protocol: 80kV, 200mA, 16 slices of 2.5mm thickness, 1 scan per 
second for 60s with a 5s delay from the start of contrast injection (370mg Iodine/mL) at a 
dosage of 1mL/kg body weight and at an injection rate of 3mL/s.  CTP studies were 
completed at baseline, 10 and 30min post ET-1 injection and then every 30min until 3hr 
post ischemia. Quantitative CBF maps from each acquired CTP study, calculated within 
5min of acquisition, were used to evaluate the perfusion in the ET-1 injection territory.  If 
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reperfusion caused CBF to rise above the target range of ~20 mL∙min-1∙100g-1 (infarction 
threshold with permanent occlusion21), a second dose of ET-1 was injected and perfusion 
was checked 10min after, before perfusion monitoring went back to half-hourly intervals.  
Physiological parameters that have an impact on CBF were monitored throughout the 
experiment. 
2.2.3 18F-FFMZ-PET Imaging for Detecting Cerebral Infarction 
FMZ is a selective, high-affinity ligand for the central benzodiazepine receptor of 
the GABA-A receptor complex22.  Since cortical neurons have a high concentration of 
GABA-A receptors, and they are sensitive to early ischemic damage, their activity within 
the brain is an indicator of neuronal integrity23.  Previous studies in humans and animals 
have shown that irreversibly damaged cortical tissue can be detected by decreased binding 
of carbon-11 (11C) labeled FMZ22,23.  FFMZ is a fluorinated analogue of flumazenil with 
similar pharmacokinetics.  FFMZ can be labelled with fluorine-18 (18F), which is 
advantageous because of the longer half-life24.  Previous studies have shown that PET 
imaging with 18F-FFMZ can be used to map the activity of GABA-A receptors in the 
human brain in the same way as 11C-FMZ 25. 
18F-FFMZ-PET imaging was performed on the GE Healthcare Discovery VCT 
PET/CT scanner in the 3D acquisition mode.  370MBq of the tracer was injected 25min 
before the start of the PET imaging (160min after first ET-1 injection).  A CT scan was 
acquired for attenuation correction. For the PET imaging, 5 frames of 300s duration each 
(25min total time) were acquired on forty-seven 3.3mm thick slices.  The 5 frames were 
averaged together at all slice locations.  
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2.2.4 Data Analysis 
For consistency, all CTP functional maps were calculated by one author using 
delay-insensitive deconvolution software (CT Perfusion 5 GE Healthcare, Waukesha, WI) 
as described previously26.  For each pig, CBF maps from each CTP imaging time point 
were co-registered, and the median value of each pixel was found using Matlab, to generate 
a median CBF map. The median CBF map was then co-registered with the PET images, 
average images (perfusion-weighted maps) from the baseline CTP study, and blood volume 
(BV) maps at 10min after the first ET-1 injection.  All image registration was manually 
performed with rigid 3D registration in Analyze 11 (Mayo Clinic, Biomedical 
Engineering).  The average image was used to draw regions of interest (ROIs) covering the 
cortex on the affected and contralateral sides on all slices containing a defect in 18F-FFMZ 
uptake.  These ROIs were then superimposed onto all other co-registered images.  Infarct 
pixels were identified on PET images as having signal less than the average minus 2 
standard deviations from the contralateral ROI.  Since GABA-A receptors are located 
primarily in the grey matter27, the average image was used to segment out white matter by 
removing any pixels where the CT number was less than 40 HU.  To avoid the influence 
of large blood vessels on parenchymal perfusion, the BV map was used to exclude blood 
vessel pixels if they had a BV greater than the average plus 2 standard deviations from the 
affected side ROI.  Additionally, pixels with median CBF greater than 100 mL∙min-1∙100g-
1 were also considered to be blood vessels and excluded from analysis.  The remaining 
infarct and non-infarct grey matter ROIs were then superimposed onto the median CBF 
map and pixel values were imported into an in-house Matlab program for logistic 
regression and ROC analysis (Figure 2.1).  This process was repeated for each animal that 
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had a defect in 18F-FFMZ uptake.  The CBF values that corresponded to the optimal 
operating point of the ROC curve (the point closest to the top left corner)28 for each animal 
were averaged together to determine the CBF threshold for infarction after 3h of ischemia.  
All analysis of images and data was performed by one author (EAW). 
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Figure 2.1: Image analysis method 
 
Fig. 2.1 Infarct (pink) was identified on a PET image (top left) acquired 160-185min after 
ET-1 injection as pixels in the affected side ROI with signal below the infarction threshold 
derived from the contralateral ROI.  Pixels with signal above this threshold were classified 
as non-infarct (yellow).  The average image (top right) was used to segment out white 
matter.  Blood vessels were identified on the BV map (bottom left) using a threshold 
derived from the affected side ROI (see text).  Grey matter, vessel-less infarct and non-
infarct ROIs were then superimposed onto the median CBF map (bottom right). 
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2.3 Results 
6 out of 11 animals had irreversible tissue damage (i.e. uptake defect upon 18F-
FFMZ imaging) and were included in the analysis.  After removing vessel pixels, the 
volumes of grey matter infarct determined by the PET threshold for these animals were 
2.96, 0.74, 2.30, 0.96, 0.97, and 0.80mL, giving an average grey matter infarct volume of 
1.46 ± 0.38mL.  3 of the 6 animals that developed infarction required a second ET-1 
injection to maintain depressed CBF in the ischemic territory. 
The average relative CBF (rCBF normalized to contralateral grey matter) in the 
grey matter infarct region was calculated at each CTP imaging time point, for each animal.  
The average relative CBF value in the infarct regions over all animals and CTP imaging 
time points was 42 ± 16%.  Figure 2.2 shows the average rCBF in the infarct region over 
time.  On average, 60min after the 1st ET-1 injection rCBF dropped to ~40% and remained 
there for the duration of the experiment. 
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Figure 2.2: Average relative CBF of infarct ROIs 
 
Fig. 2.2: Average relative CBF value from the infarct regions of the 6 animals at each time 
point.  Error bars indicate standard error. 
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 The infarct CBF histograms for each animal were normalized by scaling the number 
of infarct pixels in each bin up by the ratio of the total penumbra/oligemia pixels to the 
total infarct pixels (this scaling operation equalized the number of pixels in the infarct and 
penumbra/oligemia histograms).  This normalization did not affect the ROC analysis 
because the relative frequencies of the CBF values were not changed, but it was necessary 
to prevent bias in the logistic regression caused by having a much greater number of pixels 
in the penumbra/oligemia group than in the infarct group.  CBF histograms for each animal, 
and 18F-FFMZ-PET and CBF maps from the slice with the largest extent of infarct for each 
animal can be found in Appendix A.  Matlab was used to perform a binary logistic 
regression on the normalized histogram data for each animal.  The probability of infarction 
predicted by logistic regression is plotted against CBF for each animal in Figure 2.3.  The 
average of the 6 CBF values that corresponded to a 75% predicted probability of infarction 
in each animal was 4.5 ± 2.6 mL∙min-1∙100g-1. 
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Figure 2.3: Predicted probability of infarction versus CBF 
 
Fig. 2.3: Predicted probability of infarction from logistic regression plotted against CBF 
for each animal. The average of the CBF values that corresponded to a 75% predicted 
probability of infarction was approximately 4.5 ± 2.6 mL∙min-1∙100g-1. 
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Figure 2.4 shows the ROC curve for each animal.  The average of the CBF values 
corresponding to the optimal operating points of the ROC curves28 was 12.6 ± 2.8 mL∙min-
1∙100g-1.  The sensitivity, specificity, and accuracy for infarct detection corresponding to 
the threshold in each animal, and the area under curve (AUC) can be found in Table 2.1. 
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Figure 2.4: ROC curves for each animal 
 
Fig. 2.4: ROC curves plotted for each of the 6 animals.  Table 1 lists the CBF threshold 
derived from the optimal operating point of the ROC curve for each animal, and the 
corresponding sensitivity, specificity, accuracy, and AUC. 
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Table 2.1: ROC parameters for each animal 
Animal Threshold 
(mL∙min-1∙100g-1) 
Sensitivity Specificity Accuracy AUC 
1 10.1 0.80 0.74 0.77 0.8333 
2 8.9 0.80 0.86 0.83 0.8908 
3 15.0 0.74 0.70 0.72 0.7650 
4 13.2 0.68 0.72 0.70 0.7528 
5 12.1 0.75 0.69 0.72 0.7750 
6 16.2 0.71 0.75 0.73 0.8110 
The relevant parameters from the ROC analysis for each animal.  The CBF threshold for 
infarction was the CBF value that corresponded to the optimal operating point of the ROC 
curve.  AUC stands for area-under-curve. 
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2.4 Discussion 
This study used a porcine model of ET-1 induced cerebral ischemia to determine a 
CTP-derived CBF threshold for infarction as determined by 18F-FFMZ-PET imaging after 
3 hours of ischemia.  A threshold of 12.6 mL∙min-1∙100g-1 was determined using ROC 
analysis.  Previous animal studies have shown that the threshold for infarction is time 
dependent, dropping from 17-24 mL∙min-1∙100g-1 for permanent occlusion to 12 mL∙min-
1∙100g-1 for occlusion lasting only 3 hours21,29.   
CTP-based time dependent thresholds for infarct core could be important for 
identifying late presenting or wake-up ischemic stroke patients that may still benefit from 
therapy1.  Furthermore, time-dependent thresholds for infarction could be used to predict 
infarct growth in the time between admission imaging and reperfusion.  This knowledge 
would be useful when deciding whether it is worthwhile to transfer a patient from a regional 
hospital to an IAT capable tertiary care hospital.  
Prior perfusion threshold derivation studies could be affected by methodological 
problems.  Many studies measure CBF during the acute phase of stroke, but do not 
determine the tissue outcome until several days or even weeks later3-5 introducing the 
uncertainty of infarct expansion in the interim.  Furthermore, some studies use sub-optimal 
imaging data sets where the degree of reperfusion is not known4.  With the experimental 
procedure used in this study CBF measurements and tissue outcome can be determined 
contemporaneously, eliminating the error caused by infarct expansion.  This model also 
allows consistent monitoring of CBF using CTP, which gives information about the extent 
of reperfusion in the ischemic tissue.    
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The experimental model used in this study has several advantages over other animal 
models. The model used by Jones et al involved surgery to expose the MCA, so it could be 
occluded using a ligature29.  This is an example of a broader category of models which 
induce ischemia by occluding the MCA, generally using either an intra-arterial catheter30 
or by exposing the MCA and applying a clip or ligature29.  Implementing these models of 
acute ischemia in pigs can be problematic for several reasons; the rete mirabile makes it 
impossible to use an intra-arterial catheter14, and using a clip or ligature requires very 
invasive surgical procedures such as an osteotomy on the orbital rim15 or removal of an 
eye16.  The ET-1 insult used in this study circumvents these difficulties since the only 
surgeries required are an incision on the scalp and a small burr hole in the skull (~2mm 
diameter).  The less traumatic approach increases the ability to maintain the animal at its 
basal physiological state throughout the experiment.  This is supported by the fact that in 
the Jones study 13 of the 33 monkeys had to be excluded from the data analysis because of 
subarachnoid hemorrhage, problems with the ligature or other technical issues29 whereas 
in this study none of the 11 animals experienced these problems. 
In animals 1, 2, and 6 the first dose, administered at the start of the experiment, was 
able to maintain rCBF in the final infarct region below 50% for most of the experiment.  
However, in animals 3, 4, and 5 the effect of the first dose was transient and a second dose 
was required.  The second dose was given 90min after the first dose in animal 4 and 30min 
after the first dose in animal 5, the average rCBF for the remainder of the experiments 
dropped to ~37% and ~32% respectively in the final infarct regions.  In animal 3, the 
second dose was given 90min into the experiment, causing a transient decrease in rCBF to 
43% before it rose above 50% again 150min into the experiment.  In this animal the second 
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dose may have been given too late to counteract the reactive hyperemia associated with 
reperfusion31,32.  There was some variation in response to ET-1 injections, but variation in 
CBF reduction is to be expected in animal models of stroke.  In the study by Jones et al 
where cerebral ischemia was initiated in monkeys by ligating the MCA, the average CBF 
after ligation in the insular cortex was 17 ± 16 mL∙min-1∙100g-1 29, in this study the average 
CBF across all animals and time points after the first ET-1 injection was 15 ± 5 mL∙min-
1∙100g-1.  On average, rCBF in the final infarct tissue dropped to 56% for the first 30min 
of the experiment, from the 1hr time point until the end of the experiment rCBF was 
maintained at ~40%.  Although the cerebral ischemia caused by ET-1 injections does not 
always replicate clinical cases of stroke, the model is still suitable for this study, where the 
objective is to cause a reduction in CBF leading to infarction, then determine a CBF 
threshold for distinguishing salvaged tissue from tissue which progressed to infarction. 
Reperfusion and subsequent reactive hyperemia of the ischemic tissue after the first 
ET-1 injection is problematic in this model for several reasons.  Premature reperfusion 
prevents ischemic tissue from progressing to infarction, this was the main reason that 5 of 
11 animals did not develop irreversible tissue damage.  When reperfusion occurs midway 
through the experiment it can be difficult to accurately define the ischemia duration.  
Lastly, some tissue progresses to infarction despite having a relatively high CBF at many 
time points during the experiment, either due to a weak response to the first injection or 
premature reperfusion and associated reactive hyperemia after the first injection wears off.  
This can result in high median CBF in the infarct regions leading to overestimation of the 
infarction threshold.  For example, the average rCBF in the final infarct region for animal 
6 was below 30% between the 30min and 120min time points and above 40% in the final 
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three time points.  It is possible that infarction was due to CBF dropping to an average 
value of 9.4 mL∙min-1∙100g-1 for 30-90min in the middle of the experiment, and the higher 
CBF at the other time points resulted in an overestimated threshold of 16.2 mL∙min-1∙100g-
1 being derived.  Using the median CBF value rather than the average CBF lessens the 
effect that reperfusion has on the derivation of a threshold.   
In our experiments, reperfusion was partially mitigated by using semi-continuous 
CBF monitoring with CTP at 30min intervals to identify when reperfusion had started, so 
that another dose of ET-1 could be given.  At each CTP imaging time point the CBF maps 
were calculated on a work station in the CT scanner suite within ~5-8min of completing 
the scanning, to monitor for reperfusion from the ET-1 effects wearing off.  This method 
effectively limited reperfusion of the ischemic tissue, as the average rCBF in the final 
infarct region was below 50% for the duration of the experiment in 5 of 6 animals, and the 
average infarct rCBF across all animals and time points was 42 ± 16%.   
2.5 Conclusion 
The objective of this study was to determine a CBF threshold for infarction after 3 
hours of ischemia.  ROC analysis was used to find a threshold of 12.6 mL∙min-1∙100g-1, 
which agrees well with the value of 12 mL∙min-1∙100g-1 determined by Jones et al in 198129.  
The ET-1 model of acute stroke used in this study is easier to implement then other large 
animal stroke models.  Despite some variation in response to ET-1 injections and instances 
of premature reperfusion, the model is comparable to other animal stroke models for the 
study objective. 
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Chapter 3  
3 Impact of Truncation Artifacts on CT Perfusion-derived 
CBV, CBF, and Time-to-Maximum Measurements in 
Ischemic Stroke Patients 
3.1 Introduction 
CTP has become common in AIS as a tool for quantifying the extent of irreversibly 
damaged infarct core and salvageable penumbra1,2.  CT is advantageous in AIS since it is 
more accessible than MRI3 and can be performed without screening patients for metal 
implants and other MRI contraindications, thereby reducing door-to-needle times4.  
Applying thresholds to CTP-parameter maps can provide estimates of infarct core volume 
which are comparable to infarct volumes from DWI and follow-up CT5-7.  These infarct 
core volumes from thresholded CTP maps have been used to determine eligibility for 
endovascular therapy1,2,8,9 or predicting outcome after endovascular therapy. 
However, there is still a lack of consensus about the optimal scan duration for 
ischemic stroke applications.  Scan durations vary from 40s to 120s from center-to-center10, 
despite recommendations to use a 90s-acquisition time11.  Shorter scan durations are 
desirable due to the decreased radiation dose to the patient, but shortened scan durations 
can also lead to truncation of time-density curves from ischemic tissue if the scan duration 
is not long enough to capture the complete wash-in and wash-out of the contrast agent.  In 
AIS patients, since the contrast agent must travel through stenotic arteries or collateral 
circulation, the arrival time at ischemic tissue can be longer than 35s 12. Furthermore, once 
contrast reaches the ischemic tissue, decreased perfusion pressure can cause the washout 
to take 10-20s longer than in normal tissue13.  The delayed wash-in and washout of contrast 
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agent in ischemic tissue could result in truncated ischemic tissue time-density curves in 44 
to 67% of cases10,14, particularly for scan durations shorter than 60s (Figure 3.1). 
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Figure 3.1: Truncation of ischemic tissue TDCs 
 
Fig 3.1: Illustration of contrast washout from ischemic tissue being missed when short 
(e.g. 40 seconds, red line) scan durations are used for brain CTP in stroke patients.  
Deconvolution of truncated TDCs can lead to errors in calculation of hemodynamic 
parameters, and by extension, over- or underestimated infarct volumes when thresholds 
are applied to parameter maps. 
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Previous studies showed that truncation artifacts can result in underestimated CTP 
parameters12,15-17, and therefore, under/over-estimated infarct volumes derived by applying 
thresholds9,12,15,17,18. 
 In a previous publication, CTP infarction thresholds for different times from 
admission to reperfusion were derived using commercially available perfusion software 
(CTP4D, GE Healthcare, Waukesha, WI)5.  The effects of truncation on perfusion 
parameters and the optimal scan duration18 to avoid such effects could be dependent on 
the details of the deconvolution algorithm used to analyze the acquired data.  To 
investigate the impact of truncation on CTP parameters calculated by this software and 
clarify the optimal scan duration to be used with these previously derived thresholds, 
CTP parameter maps were computed in AIS patients for five scan durations ranging from 
40-150s, using the same software and processing procedures as in the previous 
publication5.  Median values in ischemic and unaffected tissue were found for each scan 
duration, and the shortest scan duration that provided volume estimates within ±2mL of 
the volume from the 150s scan duration was determined for two CBF thresholds. 
3.2 Methods 
3.2.1 Patients 
 Inclusion criteria were as follows: a) ischemic stroke symptoms, b) age > 18 years, 
c) baseline imaging including CTP performed within 12 hours of symptom onset, and 
before initiation of therapy, and d) follow-up MRI or CT performed at 24 hours to delineate 
infarct extent.  Exclusion criteria were as follows: a) intracranial hemorrhage at baseline 
CT, b) previous stroke in ipsilateral hemisphere, c) participation in investigational drug or 
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therapy trial, d) motion in admission CTP not amenable to correction.  Retrospective 
review of consecutive patients from the PRove-IT database (NCT02184936) identified 65 
patients meeting the inclusion and exclusion criteria for the study.  The local ethics board 
approved this retrospective data review study. 
3.2.2 Image Acquisition 
 CT imaging was performed on a 64-slice CT scanner (Lightspeed; General Electric 
Healthcare, Waukesha, WI).  45mL of contrast material (68% ioversol, Optiray 320; 
Mallinckrodt Pharmaceuticals, St Louis, Mo) was injected at 4.5mL/s followed by a 40mL 
saline chaser at 6mL/s.  Axial shuttle mode was used to cover an 8cm section of the brain 
with a 5mm slice thickness.  A two-phase scanning protocol was used where scanning 
started 5s after contrast injection5, in the first phase images were acquired every 2.8s for 
60s, and in the second phase images were acquired every 15s for 90s.  Other acquisition 
parameters were 80kV, 350mA, standard reconstruction filter, and 23cm display field of 
view.  NCCT or DWI was acquired for final infarct delineation in all patients between 24 
and 48h post symptom onset5. 
3.2.3 CTP Postprocessing 
 CBV, CBF, and Tmax maps were computed using a commercially available delay-
insensitive software package (CTP4D, GE Healthcare, Waukesha, WI).  The AIF was 
obtained from a 2x2 voxel ROI in the basilar artery and corrected for partial volume 
averaging using the VOF, obtained from an ROI in the posterior superior sagittal sinus.  In 
cases where the AIF could not be obtained from the basilar artery it was selected from the 
contralateral anterior or middle cerebral artery.  In-plane patient motion was corrected 
using automated software (CTP4D, GE Healthcare, Waukesha, WI).  Maps of CBF 
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(mL∙min-1∙100g-1), cerebral blood volume (CBV) (mL/100g), and Tmax (seconds) were 
calculated by deconvolving the partial volume corrected AIF from the tissue time-density 
curves (TDCs).  Dynamic CTP images over the first pass of contrast were averaged to 
create average maps, which were used as source images for co-registration with follow-up 
NCCT or DWI.  Shorter scan durations were simulated by sequentially deleting frames 
from the end of the CTP acquisitions to create 40, 60, 90, and 120s versions of each 150s 
CTP study.  For each patient, CBV, CBF, and Tmax maps were computed for all scan 
durations.  ROIs used to define the arterial input function and venous output function were 
saved, so that the arterial input function, venous output function, and all other post-
processing variables could be kept the same for computing maps from all scan durations. 
3.2.4 Image Analysis 
 Follow-up CT or MR images were co-registered with average images from the 
admission CTP, details of the registration were published elsewhere19.  ROIs drawn using 
the follow-up CT/MR images to delineate the infarct, ipsilateral non-infarct (tissue in 
ipsilateral hemisphere outside infarct ROI), and contralateral tissue5, were superimposed 
onto CBV, CBF, and Tmax maps from all scan durations.  Median CBV, CBF, and Tmax 
values from each ROI were found for all scan durations. 
For CBF maps from all scan durations for each patient, one infarction threshold for 
onset to reperfusion time <4.5h (CBF<7 mL∙min-1∙100g-1) and one infarction threshold for 
onset to reperfusion time >4.5-6h (7<CBF<13 mL∙min-1∙100g-1)5 were applied to each 
5mm slice, and the total infarct volume quantified by each threshold was calculated.   
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3.2.5 Statistical Analysis 
 Statistical analysis was performed in SPSS (IBM SPSS Statistics for Windows, 
version 20.0, IBM Corporation, Armonk, NY), p<0.05 was considered significant.  One-
way repeated measures ANOVA was used to assess the effect of scan duration on median 
CBV, CBF, and Tmax values in the infarct, ipsilateral non-infarct, and contralateral ROIs.  
Mauchly’s test was used to test the assumption of sphericity for all one-way repeated 
measures ANOVAs20.  In case of non-sphericity, the degrees of freedom were adjusted 
using the Greenhouse and Geisser method21 to reduce the risk of type I error.  Adjusted 
degrees of freedom were reported in brackets with the F-statistic for all one-way repeated 
measures ANOVA.  If the effect of scan duration was significant, then pairwise paired t-
tests with the Bonferroni correction for multiple comparisons were performed22.   
Infarct volumes derived by previously mentioned CBF thresholds from the 120, 90, 
60, and 40s scans were tested for statistical equivalence with their corresponding volumes 
from the 150s scan using two one-sided t-test (TOST).  In TOST, volumes measured from 
two different scan durations are equivalent if their difference () is significantly lower than 
a predetermined upper equivalence bound (Δu), and significantly higher than a 
predetermined lower equivalence bound (Δl)23-25.  For this study Δl and Δu were defined as 
±2mL, since this corresponded to 10% of the smallest infarct volume threshold used to 
determine eligibility for endovascular therapy in the DAWN trial (20mL)1.  The optimal 
scan duration for each threshold was defined as the shortest scan duration where the infarct 
volume was statistically equivalent, within ±2mL, to the infarct volume from the 150s scan 
in a TOST procedure.  Additionally, the number of patients where infarct volume derived 
by each threshold fluctuated by more than ±2mL relative to that patient’s corresponding 
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infarct volume from the 150s scan was reported for all shortened scan durations.  Median 
CBV, CBF, and Tmax values were reported as the average ± standard error, and average 
differences in threshold-derived volume between scan durations were reported with their 
95% CIs unless indicated otherwise.  Error bars on all figures indicate standard error unless 
stated otherwise in the figure caption.  
3.3 Results 
3.3.1 Patients 
 65 patients were included in the study, 46% were male and 54% were female.  The 
average age was 70.0 ± 12.4 (standard deviation) years.  8 patients without infarct on 
follow-up images were not included in the infarct region analysis, while all patients were 
included in the ipsilateral non-infarct and contralateral region analysis and TOST of 
threshold-derived volumes. 
3.3.2 Median Parameter Values 
3.3.2.1 CBV 
 Scan duration had a significant effect on median CBV in the infarct ROI (F[2,99] = 
120.1, p<0.001), ipsilateral non-infarct ROI (F[3,174] = 85.0, p<0.001), and contralateral 
ROI (F[3,159] = 118.2, p<0.001).  Panel A of Figure 3.2 shows the average median CBV 
value in the three ROIs for each scan duration, post-hoc paired samples t-tests with the 
Bonferroni correction showed that for all three ROIs, median CBV was different for all 
pairwise scan duration comparisons (p<0.01).   
 Truncation had the greatest effect in the infarct ROI, where decreasing the scan 
duration to 120, 90, 60, and 40s underestimated median CBV by 0.2 ± 0.04, 0.7 ± 0.1, 1.1 
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± 0.1, and 1.6 ± 0.1 mL/100g respectively, relative to that from the 150s scan duration.  In 
the ipsilateral non-infarct and contralateral ROIs decreasing the scan duration from 150 to 
40s underestimated median CBV by 1.3 ± 0.1 and 1.2 ± 0.1 mL/100g respectively. 
3.3.2.2 CBF 
 The effect of scan duration on median CBF was not significant for the infarct 
(F[3,155] = 2.3, p = 0.086), ipsilateral non-infarct (F[3,185] = 2.4, p = 0.075) or contralateral 
(F[3,197] = 0.742, p = 0.531) ROI.  Median CBF for each of the three ROIs is plotted against 
scan duration in Panel B of Figure 3.2. 
3.3.2.3 Tmax 
 Median Tmax was significantly affected by scan duration in the infarct (F[1,80] = 
108.0, p<0.001), ipsilateral non-infarct (F[2,110] = 156.1, p<0.001), and contralateral (F[2,150] 
= 116.5, p<0.001) ROI.  Median Tmax from each ROI is plotted against scan duration in 
Panel C of Figure 3.2.  Post-hoc paired t-tests with the Bonferroni correction showed that 
for all three ROIs, all pairwise comparisons of median Tmax from different scan duration 
were significantly different (p<0.001). 
 For the infarct ROI, decreasing the scan duration from 150s to 120, 90, 60, and 40s 
underestimated median Tmax value by 1.1 ± 0.2, 3.2 ± 0.4, 6.4 ± 0.6, and 9.8 ± 0.9s relative 
to that from the 150s scan duration. For the ipsilateral non-infarct and contralateral ROI, 
decreasing the scan duration from 150 to 40s underestimated median Tmax by 2.5 ± 0.2 and 
1.5 ± 0.1s respectively, relative to that from 150s scan duration.   
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Figure 3.2: Median CBV, CBF, and Tmax versus scan duration in infarct, ipsilateral 
non-infarct, and contralateral ROIs 
 
Fig. 3.2: CBV (A), CBF (B), and time-to-maximum (Tmax) (C) in infarct (dashed), 
ipsilateral non-infarct (dotted), and contralateral (solid) ROIs at each scan duration.  Scan 
duration had a significant effect on median CBV and Tmax in all three ROIs (p<0.001) but 
the effect on median CBF was not significant for any of the ROIs (p>0.05).  Error bars 
represent standard error. 
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3.3.3 Threshold-derived Infarct Volumes 
 The volume of infarct core for onset to reperfusion time <4.5h identified by the 
CBF<7 mL∙min-1∙100g-1 threshold was equivalent to the volume from the 150s scan in 
TOST for all shorter scan durations (p<0.001).  The infarct volume for onset to reperfusion 
time >4.5-6h derived by the thresholds 7<CBF<13 mL∙min-1∙100g-1 was also equivalent to 
the volume from the 150s scan in TOST for all shorter scan durations (p<0.01).  For CBF<7 
mL∙min-1∙100g-1, changing the scan duration from 150s to 120, 90, 60, and 40s decreased 
infarct volume (mL) by (mean (95% CI)): -0.20 (-0.31 to -0.10), -0.13 (-0.28 to -0.02), -
0.28 (-0.46 to -0.11), and -0.61 (-1.00 to -0.22) respectively, and resulted in 0 (0%), 0 (0%), 
2 (3%), and 11 (17%) patients where the infarct volume changed by more than ±2mL 
relative to their value from the 150s scan.  When scan duration was decreased from 150s 
to 120, 90, 60, and 40s the infarct volume (mL) for onset to reperfusion time >4.5-6h  
defined by 7<CBF<13 mL∙min-1∙100g-1 changed by -0.29 (-0.52 to -0.05), -0.40 (-0.65 to 
-0.15), -0.69 (-1.10 to -0.27), and -1.31 (-1.83 to -0.78) respectively, and resulted in 3 (5%), 
3 (5%), 8 (12%), and 23 (35%) patients where the infarct volume changed by more than 
±2mL relative to their value from the 150s scan.  Figure 3.3 shows the 95% CIs, and range 
of infarct volume changes relative to the volume from the 150s duration for both thresholds.  
Table 3.1 shows the average infarct volume derived by each threshold for all scan 
durations. 
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Figure 3.3: Confidence intervals and range of volume differences relative to 150s scan 
for CBF<7 mL∙min-1∙100g-1 and 7<CBF<13 mL∙min-1∙100g-1 
 
Fig. 3.3: Average and 95% CIs (solid lines with markers), and range (dotted lines) of 
differences in infarct volume relative to the 150s scan for CBF<7 mL∙min-1∙100g-1 (A) and 
CBF<13 mL∙min-1∙100g-1 (B).  Scan durations of 120, 90, 60, and 40s indicated by circles, 
stars, squares, and diamonds respectively, and vertical dashed lines represent the 
equivalence boundaries for the two-one-sided t-test procedures (±2mL).  The volumes 
derived by CBF<7 mL∙min-1∙100g-1 (p<0.001) and CBF<13 mL∙min-1∙100g-1 (p<0.01) 
were equivalent to the 150s scan within ± 2mL for all shorter scan durations. 
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Table 3.1: Average ± S.E. tissue volumes specified by CBF thresholds 
Threshold 
Infarct Volume at Each Scan Duration 
150s 120s 90s 60s 40s 
CBF<7 mL∙min-1∙100g-1 17.01 ± 
1.91 
16.81 ± 
1.92* 
16.88 ± 
1.92* 
16.73 ± 
1.91* 
16.41 ± 
1.91* 
7<CBF<13 mL∙min-1∙100g-1 37.06 ± 
2.52 
36.77 ± 
2.52* 
36.66 ± 
2.53* 
36.37 ± 
2.55* 
35.75 ± 
2.55* 
Table 3.1: Average infarct volumes for onset to reperfusion time <4.5h (cerebral blood 
flow (CBF) <7 mL∙min-1∙100g-1), and onset to reperfusion time >4.5-6h (7<CBF<13 
mL∙min-1∙100g-1) for each scan duration.  Volumes that were statistically equivalent 
(p<0.01), within ±2mL, as evaluated by two-one-sided tests, to the corresponding volume 
measured from the 150s scan duration are indicated by an asterisk (*). 
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3.4 Discussion 
CTP is used in AIS to estimate the volume of infarct core and salvageable tissue at 
admission to the hospital by applying thresholds to parameter maps, however the optimal 
duration of CTP scans for AIS applications is not yet clear.  The results of this study show 
that CBV and Tmax calculated by GE Healthcare’s CTP4D software are dependent on scan 
duration, whereas CBF calculations by this software, and therefore infarct volumes 
quantified by previously derived CBF thresholds5, are independent of scan duration.  
Truncation effects on median CBV and Tmax were most severe in the infarct ROI due to 
delayed bolus arrival and slow contrast washout12,13, but significant truncation effects were 
also seen in the ipsilateral-salvaged and contralateral ROIs.  This agrees with results from 
prior studies which found that truncation artifacts result in underestimated CBV in PWI15 
and CTP scans16, and by extension, overestimated infarct volumes when CBV thresholds 
are applied.  Contrastingly, median CBF changed by only 1.4-6.5% of values from the 150s 
scan, and similarly, time-dependent infarct volumes for onset to reperfusion time <4.5h 
and >4.5-6h derived using CBF thresholds from scan durations ranging from 40 to 120s 
were all equivalent to the volumes derived from the 150s scan in TOST procedures, within 
±2mL (p<0.025).  This means that when CBF thresholds are used to define the infarct core, 
scan duration can be reduced to 40s without affecting treatment decisions made based on 
infarct volume.  For the 2-phase CTP protocol used in this study, this would remove the 
entire 2nd phase and one-third of the 1st phase of the scan, or 13 out of 27 total time points.  
This would have decreased radiation dose by ~48%, from ~5mSv26 to ~2.6mSv. 
These results agree with prior CTP17 and PWI12 studies using deconvolution based 
on standard singular value decomposition, oscillation-index regulated singular value 
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decomposition12, and circular singular value decomposition17.  These studies which found 
CBF lesion volumes were independent of scan duration within the clinically relevant range 
of scan durations (>40s)17, and that reversal of CBF lesions occurred in only ~3% of cases 
when scan duration was decreased from 110 to 40s12.  Although these studies established 
the effect of truncation on CTP parameters and threshold-derived volumes, optimal 
minimum scan durations that result in stable infarct/penumbra volume estimates were not 
reported.  A prior study by Kasasbeh et al, which used a research version of RAPID 
(RAPID, iSchemaView, Menlo Park, CA), proposed calculating personalized minimum 
scan durations depending on the arrival time and width of a patient’s venous output 
function18.  However, the shape of the venous output function is determined by venous 
drainage of contrast from both ischemic and normal tissue.  This could be an issue when 
determining the optimal scan duration for AIS patients since it is likely that the arrival time 
and width of the venous output function is not representative of the wash-in and washout 
of contrast from ischemic tissue.  Furthermore, calculating the patient’s optimal CTP scan 
duration based on venous output function shape requires an additional pre-scan with a bolus 
injection of contrast to measure the venous output function.  This extra radiation dose is 
counter-productive to using a shortened scan duration to limit radiation dose.  In addition 
to personalized scan durations, this study also recommended a population-based optimal 
CTP scan duration of 70s, since infarct (relative CBF<30%) and penumbra (Tmax>6s) 
volumes quantified with RAPID (iSchemaView, Menlo Park, CA) from a 70s scan 
remained within ±10% of their respective volumes from a 90s scan18.  The results of this 
study suggest that if CTP4D (GE Healthcare, Waukesha, WI) is used for map computation, 
and previously derived time-dependent CBF thresholds are used to determine tissue 
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viability, then scan duration can be decreased to 40s, further reducing radiation dose, 
without affecting tissue volumes by more than an average of ±2mL. 
Relatively conservative equivalence bounds of ±2mL were chosen for TOST in this 
study because they were equal to 10% of the smallest CTP-derived infarct volume used to 
determine eligibility for endovascular therapy in the DAWN trial1.  In addition to 
performing TOST we also reported the number of patients where infarct volumes 
determined by each threshold changed by more than ±2mL relative to the 150s for each 
scan duration.  Although infarct volumes derived from 40s scans by the thresholds CBF<7 
and 13 mL∙min-1∙100g-1 were equivalent to the 150s scan by TOST, there were 11 (17%) 
and 23 (35%) patients respectively where the infarct volume derived by each threshold 
changed by more than ±2mL relative to the 150s scan, however only 2 (3%) and 4 (6%) 
patients experienced a change of greater than 4mL.  Therefore, shortening scan duration to 
40s may cause small infarct volume fluctuations in up to 35% of patients, but these 
fluctuations are smaller than 4mL in most cases, and the average infarct volume change is 
less than ±2mL. 
Under- or over-estimation of the infarct or penumbra volume due to truncation is 
problematic when mismatch criteria are used to determine treatment eligibility for AIS 
patients. Penumbra volumes1 quantified by Tmax>6s could be underestimated at short scan 
durations due to truncation, causing patients to be misclassified as ineligible for 
endovascular therapy due to lack of salvageable tissue when they may have still benefited 
from reperfusion.  Similarly, infarct volumes27 determined by CBV<2mL/100g may be 
overestimated with short scan durations, resulting in patients being incorrectly classified 
as ineligible for endovascular therapy.  Our results indicate that AIS triaging will not be 
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affected by truncation artifacts for scan durations longer than 40s if maps are computed 
with GE Healthcare’s CTP4D (CTP4D, GE Healthcare, Waukesha, WI) and previously 
derived time-dependent CBF thresholds for infarction5 are used to define tissue viability. 
CBF is determined by the upslope of the tissue time-density curve28, so unless 
truncation affects this upslope, CBF is estimated relatively error free.  Based on 
conservation of mass, CBV can be calculated as the area under the tissue time-density curve 
divided by the area under the arterial input function29. With truncation, the area under the 
time-density curve of ischemic tissue with delayed contrast wash-in and washout decreases 
more rapidly than the area under the arterial input function resulting in underestimated 
CBV.  MTT is equal to the CBV divided by CBF, as required by the Central Volume 
Principle30, therefore MTT also decreases with shorter scan durations.  This also applies to 
Tmax, since the software used in this study calculates Tmax as T0 plus half the MTT
5.  These 
theoretical considerations explain why CBV and Tmax were affected by truncation artifacts 
while CBF was not.  It also explains why the limited truncation effect on CBF observed in 
this study was similar to what was seen in studies using other deconvolution software 
packages10,12, since CBF is dependent on the upslope of the tissue time-density curve, 
regardless of what software is used to produce maps. 
This study had several limitations.  As mentioned before, CTP maps vary 
depending on the software used to compute them31, therefore optimal scan durations from 
this study may not be directly applicable to other software packages.  However, we expect 
the general conclusion that CBF is relatively independent of scan duration, would remain 
the same since it is calculated based on the upslope of the tissue time-density curve 
regardless of software.  CTP was acquired using a 2-phase protocol where images were 
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acquired once every 15s in the second phase, this made it impossible to investigate scan 
durations in between time points in the second phase.  Analysis was also limited only to 
scan durations longer than 40s since this is the shortest scan duration used clinically for 
brain CTP.  Lastly, this was a retrospective study with a relatively small group of patients.  
The results of this study should be confirmed in a prospectively designed study with a 
larger group of patients. 
3.5 Conclusion 
 CBF remains constant and infarct volumes estimated using previously derived5 
CBF thresholds are equivalent within ±2mL for scan durations ranging from 40 to 150s, 
whereas CBV and Tmax decrease at shorter scan durations due to truncation errors.  If these 
CBF thresholds are used to determine treatment eligibility, then scan duration can be 
decreased to 40s to reduce radiation dose to AIS patients by ~48% without triaging being 
affected by truncation artifacts. 
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Chapter 4  
4 Reperfusion Assessed by CT Perfusion is a More 
Specific and Accurate Predictor of Functional Outcome 
than Modified Thrombolysis in Cerebral Infarction Score 
in Ischemic Stroke Patients Treated with Intra-Arterial 
Therapy 
4.1 Introduction 
 IAT has become the standard of care for acute ischemic stroke patients with large 
vessel occlusion after multiple clinical trials demonstrated superior efficacy compared to 
thrombolysis alone1-6. More recently, results from the DEFUSE-3 and DAWN trials have 
shown that IAT performed in patients selected by perfusion imaging within 16h7 and 24h8 
post symptom onset is superior to medical management alone. One secondary outcome of 
these trials was a mTICI score of 2b or 3 on post-procedural DSA, representing reperfusion 
of 50-99% and 100% of the affected vascular territory respectively9. Although mTICI 2b/3 
is a commonly accepted criterion for good reperfusion, ~15-20% of patients in the 
treatment arm of earlier trials2-6 had a poor 90-day functional outcome (90-day mRS>2) 
despite post-procedural mTICI scores of 2b/3; this number increased to ~30-35% in the 
DEFUSE-3 and DAWN trials7,8. There is a need to better measure poor reperfusion after 
IAT, to allow other treatment to be instituted as soon as possible.  A more quantitative, less 
subjective alternative to the mTICI score could be the percentage change in ischemic 
volume from admission to shortly after IAT, calculated by applying thresholds for 
ischemia10 to CTP maps obtained at admission and post-IAT11.  Prior studies have shown 
that post-procedural mTICI scores were independently associated with functional 
outcome12-14, and improved outcome prediction accuracy15.  However, relatively few 
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studies have directly compared reperfusion assessed by follow-up CTP to post-procedural 
mTICI scores as measures of post-IAT reperfusion, and as prognosticators of outcome after 
IAT. 
The objectives for this study were therefore: 1) to compare mTICI scores and a 
CTP-based reperfusion metric and 2) to determine which of these two measures of 
reperfusion was better associated with 90-day functional outcome.  We hypothesized that 
the CTP-based reperfusion metric would have a stronger association with 90-day functional 
outcome than mTICI scores.  
4.2 Methods 
4.2.1 Patient Selection 
The institutional review board approved this study and informed consent was 
obtained from each patient contributing data to the study.  Eligible patients were ischemic 
stroke patients treated by IAT, received non-contrast CT, CT Angiography, and CTP at 
hospital admission, and follow-up CTP approximately 24 hours post symptom onset, 
functional evaluation 90-days post onset with mRS, and a complete record of demographic, 
clinical and imaging variables, including mTICI score from post-procedural DSA.  
Retrospective review of consecutive acute ischemic stroke patients admitted to the 
Neuroscience Department of Azienda Ospedaliero-Universitaria di Ferrara (Italy) from 
June 2008 to September 2015 identified 118 IAT-treated patients.  Patients without onset 
CTP (n=2), 24h CTP (n=11), 90-day mRS evaluation (n=2), or those with motion in either 
onset or 24h CTP that was not amenable to correction with in-plane rigid registration (n=7) 
were excluded, leaving 96 patients for the final patient cohort (Figure 4.1). 
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Figure 4.1: Patient exclusion flow chart 
 
Fig. 4.1: Flow diagram that highlights exclusions of patients after retrospective review of 
all acute ischemic stroke (AIS) patients treated with intra-arterial therapy (IAT) between 
June 2008 and September 2015.  CTA indicates CT Angiography; CTP, CT Perfusion; 
DSA, digital subtraction angiography; mRS, modified Rankin Scale; NCCT, non-contrast 
CT. 
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4.2.2 Imaging Protocol 
 Patients underwent non-contrast CT, CT angiography, and CTP at admission, DSA 
after the IAT procedure concluded, and follow-up CTP at ~24h post admission (median 
(IQR) = 25 (22-28) hours).  All CT imaging were performed on a Lightspeed VCT scanner 
(GE Healthcare, Waukesha, WI).  Non-contrast CT and CT angiography imaging protocols 
have been described previously16.  Briefly, helical NCCT scans covered from the skull base 
to the vertex with the following parameters: 120kV, 340mA, 4 x 5 collimation, 1s rotation 
time, and table speed of 15mm/rotation16.  CTA covering from the carotid bifurcation to 
the vertex were acquired with the following parameters: 0.7mL/kg contrast (up to a 
maximum of 90mL) injected at 4mL/s, 5-10s delay from injection to start of scanning, 
120kV, 270mA, 1s rotation time, 1.25mm thick slices, and table speed of 
3.75mm/rotation16.  CTP scanning was initiated 5s after 40mL of CT contrast agent was 
power-injected at 4mL/s into an antecubital vein.  Most patients (n = 65) were scanned 
using a 2-phase protocol without axial shuttle mode; volume (4cm coverage) acquired 
every 0.5s for 50s in first phase, and every 15s for 150s in second phase, 80kV, 100mAs, 
5mm slice thickness.  Fifteen patients (n = 15) were scanned using a 2-phase protocol with 
axial shuttle mode; volume (8cm coverage) acquired every 2.8s for 60s in first phase, and 
every 15s for 135s in second phase, 80kV, 140mAs, 5mm slice thickness. Sixteen patients 
(n = 16) were scanned with a 1-phase protocol without shuttle mode; volume (4cm 
coverage) acquired every 0.5s for 50s, 80kV, 100mAs, 5mm slice thickness.  All CTP 
source images were reconstructed with the standard filter and DFOV of 25cm. 
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4.2.3 Image Analysis 
 Admission CT angiography were reviewed by two neuroradiologists (AB and EF; 
5 and 20 years of experience respectively) and assigned rLMC scores, clot burden scores, 
and pre-treatment mTICI scores.  Post-procedural mTICI scores were assessed on DSA.  
The rLMC score has been described previously17; the degree of contrast opacification of 
cerebral blood vessels is assessed in the six ASPECTS cortical regions, parasagittal anterior 
cerebral artery territory, and basal ganglia and assigned a score of 0 (artery is not visible), 
1 (artery is less prominent compared to contralateral side), or 2 (artery is equal or more 
prominent compared to contralateral side) is assigned to each region.  Scores can range 
from 0-20, with increasing rLMC score indicating better collateral circulation status.  The 
clot burden score has also been described previously18; starting from a 10-point scale, 2 
points were subtracted for lack of contrast opacification across the full cross-section in any 
part of the supraclinoid ICA, proximal M1 segment, and distal M1 segment, and 1 point 
was subtracted for each M2 branch, A1 segment and infraclinoid ICA.  Clot burden scores 
range from 0-10, with decreasing scores indicating greater thrombus extent. 
 CBV, CBF, and Tmax maps for admission and follow-up CTP studies were 
computed by one author (EW; 5 years of experience) using commercially available delay-
insensitive perfusion software (CTP4D, GE Healthcare, Waukesha, WI).  In-plane patient 
motion was corrected using an automated registration program included in the perfusion 
software.  The AIF and VOF were measured from regions of interest (ROIs) in the basilar 
artery, and superior sagittal sinus respectively.  If the AIF could not be measured from the 
basilar artery, it was measured from an ROI in the contralateral anterior cerebral artery or 
middle cerebral artery.  The VOF was used to correct for partial volume averaging in the 
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AIF, then CBF (mL∙min-1∙100g-1), CBV (mL/100g), and Tmax (seconds) maps were 
computed by deconvolving the AIF from tissue TDCs.  Dynamic images from the first pass 
of contrast were averaged to create average maps, which were used to exclude 
cerebrospinal fluid and skull using HU thresholds. 
 An ROI was drawn on the average image covering the ipsilateral hemisphere 
(excluding ventricles and old infarct, if present), this ROI was superimposed onto cerebral 
blood flow, cerebral blood volume, and time-to-maximum maps.  Blood vessel pixels were 
removed by applying thresholds to cerebral blood flow (>100 mL∙min-1∙100g-1), cerebral 
blood volume (>8mL/100g) maps, and any remaining cerebrospinal fluid or skull was 
removed by applying thresholds to the average image.  Ischemic tissue volume was then 
quantified using the threshold time-to-maximum >10s (derived in a previous study)10.   
This process was repeated for admission and follow-up CTP studies to acquire admission 
(Vadm), and 24h ischemic tissue volumes (V24h) for all patients.  To quantify tissue 
reperfusion measured by CTP, the reperfusion score (SCTP) was defined as the percentage 
change in ischemic volume from admission to 24h follow-up11. 
[1]    𝑆𝐶𝑇𝑃 =
𝑉𝑎𝑑𝑚−𝑉24ℎ
𝑉𝑎𝑑𝑚
∙ 100% 
 The maximum value of the reperfusion score was 100% (V24h = 0mL), a reperfusion 
score of 0% corresponds to no reperfusion between admission and 24h (Vadm = V24h), and 
a negative reperfusion score indicates the ischemic tissue volume increased between onset 
and 24h (V24h > Vadm). 
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4.2.4 Statistical Analysis 
4.2.4.1 Comparison of mTICI Scores to SCTP 
 Ordinal regression of post-procedural mTICI scores on SCTP was performed to 
assess the association between reperfusion predicted by post-procedural mTICI scores and 
reperfusion seen on follow-up CTP.  One-way ANOVA and post-hoc t-tests with the 
Bonferroni correction19 were used to compare the mean SCTP at different levels of post-
procedural mTICI score.  A one-sample t-test was also performed to determine if the mean 
SCTP from mTICI 3 patients was significantly less than 100%, since mTICI 3 is meant to 
indicate reperfusion of 100% of the affected vascular territory9. 
4.2.4.2 Comparison of mTICI Scores and SCTP for Predicting 
Functional Outcome 
 SCTP and other variables were compared between patients with good (mRS≤2) and 
poor (mRS>2) outcomes using either independent samples t-test (continuous variable), or 
Mann-Whitney U test (categorical variable).  Variables that were significantly different 
between good and poor outcome groups were included in a logistic regression model for 
predicting outcome with backwards, stepwise elimination of variables.  Removal of 
variables was based on the significance of the Wald statistic; the cut-off value for variable 
removal was p>0.05. 
ROC analysis was then performed to compare SCTP and the mTICI score in ability 
to determine good outcome at 90 days.  AUC was compared using methods described by 
Hanley and McNeil20.  Optimal thresholds for separating patients with good and poor 
outcomes were defined using Youden’s J statistic21.  The corresponding sensitivity, 
specificity, accuracy, PPV, and NPV of these optimal thresholds were determined.  
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Statistical analysis was performed in SPSS version 20 (IBM Corporation, Armonk, 
NJ), p<0.05 was considered significant.  Values were reported as mean ± SE unless 
indicated otherwise, error bars on figures are SE unless indicated otherwise in the figure 
caption. 
4.3 Results 
4.3.1 Comparison of mTICI Scores to SCTP 
 Out of the 96 patients included, 48% (46/96) were female (mean age (±SD) 
=70±11y) and 52% (50/96) were male (mean age (±SD) =69±11y).  The most common 
TOAST stroke subtype was cardioembolic (50/96), followed by atherothrombotic (36/96), 
undetermined (8/96), and other (dissection) (2/96).  Of the 96 patients, 32% (31/96) 
received intravenous tissue plasminogen activator (IV-tPA).  The number of patients with 
post-procedural mTICI scores of 0, 1, 2a, 2b, and 3 were 17, 6, 5, 19, and 49 respectively. 
 The association between post-procedural mTICI score and SCTP was significant in 
the ordinal logistic regression, but only 36% of the variation in SCTP was explained by the 
post-procedural mTICI score (Nagelkerke R2=0.36, p<0.001). SCTP in patients with mTICI 
scores of 2b (72.8±6.5%) and 3 (82.6±2.7) was significantly higher than in patients with 
mTICI scores of 0 (27.0±12.2%) (p<0.001 for both mTICI 2b and 3) and 1 (16.7±6.8%) 
(p≤0.001 and p<0.001 for mTICI 2b and 3 respectively) in post-hoc t-tests with the 
Bonferroni correction.  However, SCTP in patients with mTICI scores of 2a (67.7 ± 10.9%), 
2b, and 3 were not significantly different from each other (p=1.00 for all pairwise 
comparisons) (Figure 4.2).  SCTP in mTICI 3 patients (82.6±2.7%) was also significantly 
lower than the expected value of 100% (p<0.001). 
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Figure 4.2: Mean SCTP at each level of post-procedural mTICI score 
 
Fig. 4.2: Mean ± standard error reperfusion score (SCTP) at each level of the modified 
thrombolysis in cerebral infarction (mTICI) score.  Square brackets indicate lack of 
significance (p>0.05) difference in SCTP between 2 or more levels of post-procedural 
mTICI score. 
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 Interestingly, 26% (6/23) of patients with post-procedural mTICI≤1 had SCTP>50%, 
even though mTICI scores of 0 and 1 are meant to indicate no reperfusion, with no flow 
past the occlusion site and limited flow past the occlusion site respectively9.  These patients 
had SCTP ranging from 50.8-100% with an average of 84.0±8.3%, 4 of the 6 patients had 
good 90-day functional outcomes.  18% (9/49) of patients with post-procedural mTICI 
scores of 3 had SCTP<67%, despite mTICI 3 being defined as full reperfusion without any 
flow defects9.  These patients had SCTP ranging from 18.5-66.7% with an average of 
50.0±6.0%, 6 of the 9 patients had poor 90-day functional outcomes (Figure 4.3). 
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Figure 4.3: Ischemic lesion on 24h follow-up Tmax map for patient with post-
procedural mTICI score of 3 
 
Fig. 4.3: An example of the discrepancy between modified thrombolysis in cerebral 
ischemia (mTICI) 3 and reperfusion score (SCTP) assessed on pre-treatment and 24h follow-
up CT Perfusion (CTP).  A-B) Frontal (A) and sagittal (B) views from the post-procedural 
digital subtraction angiography (DSA) which was scored mTICI 3.  C-D) Average image 
(C) and time-to-maximum (Tmax) map (D) from 24h follow-up CTP showing a large 
ischemic (Tmax>10s) lesion in the left MCA territory, SCTP for this patient was 18.5%. 
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4.3.2 Comparison of mTICI Scores to SCTP for Predicting Functional 
Outcome 
 Demographic, clinical, and imaging characteristics of the patients included in the 
study are summarized in Table 4.1.  The median admission rLMC scores (p<0.05), and 
post-procedural mTICI scores (p<0.05) were higher for the good outcome group than the 
poor outcome group, and the median admission NIHSS score (p<0.001) was lower in the 
good outcome group than the poor outcome group.  Onset to admission CT time was 
unknown in 21 patients, among the other 75 patients, the mean onset to CT, and onset to 
end IAT procedure times were not significantly different between good and poor outcome 
groups.  Average SCTP in the good and poor outcome groups were 82.3±3.3 and 51.5±5.8% 
(p<0.001) respectively, and Average V24h in good and poor outcome groups were 14.9±3.2 
and 37.7±5.1mL (p<0.001) respectively. 
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Table 4.1: Demographic, clinical and imaging characteristics of the 96 patients 
included in the study 
Variable Good Outcome 
(mRS ≤ 2) 
Poor Outcome 
(mRS > 2) 
p 
Number of patients [n (% of total)] 45 (47) 51 (53) NA 
Age (y) [mean (SD)] 67.8 (11) 71.2 (11) 0.133 
Sex [n (% female)] 25 (55.6) 21 (41.2) 0.162 
Admission NIHSS score [median (IQR)] 13* (11-18) 20* (16-24) <0.001 
Admission rLMC score [median (IQR)] 14* (10-16) 11* (7-14) 0.010 
Clot burden score [median (IQR)] 6 (4-7) 6 (3-7) 0.583 
Admission mTICI score [median (IQR)] 1 (0-2) 0 (0-1) 0.094 
Vadm (mL) [mean (SE)] 84.0 (6.1) 82.2 (6.2) 0.834 
V24h (mL) [mean (SE)] 14.9* (3.2) 37.7* (5.1) <0.001 
SCTP (%) [mean (SE)] 82.3* (3.3) 51.5* (5.8) <0.001 
Post-procedural mTICI score [median (IQR)] 4* (3-4) 3* (1-4) 0.031 
IV-tPA administration [n (% receiving IV-
tPA)] 
18 (40.0) 13 (25.5) 0.283 
Symptom onset to admission CT time (min) 
[mean (SE)] 
155.8⸸ (14.4) 146.2⸸ (11.3) 0.647 
Admission CT to end procedure time (min) 
[mean (SE)] 
168.2 (11.2) 201.1 (12.3) 0.051 
Symptom onset to end procedure time (min) 
[mean (SE)] 
333.8⸸ (17.6) 347.9⸸ (16.5) 0.561 
Table 4.1: Demographic, clinical, and imaging characteristics of the patients in the good 
(n=45), and poor (n=51) outcome groups.  CT indicates computed tomography; IQR, inter-
quartile range; IV-tPA, intravenous tissue plasminogen activator; min, minutes; mRS, 
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modified Rankin Scale; mTICI, modified thrombolysis in cerebral infarction; n, number; 
NIHSS, National Institute of Health Stroke Scale; p, p-value from independent samples t-
test (parametric variables) or Mann-Whitney U test (non-parametric variables); rLMC, 
regional leptomeningeal collateral; SCTP, reperfusion score; SD, standard deviation; SE, 
standard error; V24h, 24h ischemic tissue volume; Vadm, admission ischemic tissue volume; 
y, years.    
* Significant difference (p<0.05) between good and poor outcome groups in an 
independent samples t-test (continuous variables) or Mann-Whitney U Test 
(ordinal/categorical variables). 
⸸ 10 and 11 patients in the good and poor outcome groups respectively had unknown 
symptom onset time and were excluded from the independent samples t-test. 
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 Variables that were significantly different between groups were included in a 
logistic regression model to predict mRS outcome.  In stepwise elimination, post-
procedural mTICI was removed first, followed by V24h, and admission rLMC score, leaving 
only SCTP and admission NIHSS to predict outcome with significance (p<0.001) (Table 
4.2).   
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Table 4.2: Logistic regression for predicting 90-day functional outcome based on SCTP 
and admission NIHSS 
 B SE Wald df p Odds 
Ratio 
95% CI for 
Odds Ratio 
Lower Upper 
SCTP 0.030 0.009 10.705 1 0.001 1.031 1.012 1.049 
Admission 
NIHSS 
-0.137 0.043 10.825 1 0.001 0.872 0.804 0.946 
Constant 0.048 0.964 0.003 1 0.960 1.049   
Table 4.2: Summary of statistics for the variables that remained in the backward-
elimination multivariate logistic regression for predicting 90-day outcome.  B indicates 
coefficients from the regression equation; CI, confidence interval; df, degrees of freedom; 
NIHSS, national institute of health stroke scale; p, significance of the Wald test; SCTP, 
reperfusion score; SE, standard error associated with B; Wald, Wald statistic used to test 
the significance of B values.  
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 ROC curves for predicting outcome with SCTP, versus post-procedural mTICI score 
as predictors of good outcome are plotted in Figure 4.4.  The AUC for SCTP, and mTICI 
score were, 0.717±0.053 (p<0.001), and 0.618± 0.057 (p<0.05) respectively.  SCTP had a 
significantly greater AUC than post-procedural mTICI (p<0.05). 
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Figure 4.4: ROC curves for predicting good functional outcome based on SCTP and 
post-procedural mTICI score 
 
Fig. 4.4: Receiver-operator-characteristic (ROC) curves for reperfusion score (SCTP) 
(solid), and post-procedural modified thrombolysis in cerebral ischemia (mTICI) score 
(dashed), with the diagonal line of no discrimination (dotted). 
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The optimal operating points for predicting good outcome corresponded to SCTP of 
81.5%, and mTICI score of 2b.  SCTP>81.5% had sensitivity, specificity, accuracy, PPV, 
and NPV of 0.73 (33/45), 0.69 (35/51), 0.71 (68/96), 0.67 (33/49), and 0.74 (35/47) 
respectively.  The sensitivity, specificity, accuracy, PPV, and NPV of mTICI 2b/3 were 
0.84 (38/45), 0.41 (21/51), 0.61 (59/96), 0.56 (38/68), and 0.75 (21/28) respectively.  For 
the logistic regression model, the optimal threshold for predicting good outcome 
corresponded to: 0.03*(SCTP)–0.12*(admission NIHSS)>0.30.  The sensitivity, specificity, 
accuracy, PPV, and NPV of this threshold were 0.71 (32/45), 0.82 (42/51), 0.77 (74/96), 
0.78 (32/41), and 0.76 (42/55).  SCTP>81.5% had better specificity, accuracy, and PPV 
compared to mTICI 2b/3, and the regression model had better specificity, accuracy, PPV, 
and NPV than the SCTP or mTICI threshold alone (Figure 4.5). 
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Figure 4.5: Sensitivity, specificity, accuracy, PPV, and NPV for regression model, 
SCTP > 81.5% and mTICI 2b/3 for predicting functional outcome 
 
Fig. 4.5: Sensitivity, specificity, accuracy, positive predictive value (PPV), and negative 
predictive value (NPV) of the optimal threshold for the regression model (black), 
reperfusion score (SCTP) > 81.5% (grey), and modified thrombolysis in cerebral infarction 
(mTICI) 2b/3 (white) for predicting good 90-day functional outcome. 
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4.4 Discussion 
 In clinical trials 15-35% of IAT-treated patients with mTICI 2b/3 had poor 
outcomes2-6.  Some poor outcomes may have been due to reperfusion injury22 or lack of 
salvageable tissue after long onset to recanalization times23; the discrepancy between 
patients with mTICI 2b/3 and those with good outcome may have also resulted from mTICI 
2b/3 not accurately reflecting near-complete/complete reperfusion.  Accurate 
prognosticators of reperfusion will be important as more patients are treated after results 
from DAWN and DEFUSE-3 showed the time window for IAT can be extended to 16-
24h7,8 in neuroimaging-selected patients.  This study’s objectives were to compare 
reperfusion predicted by mTICI scores to reperfusion on admission and 24h CTP (SCTP), 
and to compare mTICI score to SCTP as prognosticators of 90-day outcome. 
 Regarding objective 1, SCTP in patients with mTICI scores of 2b and 3 were 
significantly higher than in the mTICI 0 and 1 groups, but there were no significant SCTP 
differences between patients with mTICI scores of 2a, 2b, and 3, and ~18% of mTICI 3 
patients had reperfusion of less than two-thirds of the affected tissue (SCTP<67%).  
Regarding objective 2, only admission NIHSS and SCTP remained significant in a stepwise 
logistic regression for predicting outcome.  AUC was also significantly higher for SCTP 
compared to mTICI score, and the optimal SCTP threshold derived in this study 
(SCTP>81.5%) predicted good outcome with better specificity, accuracy, and PPV than 
mTICI 2b/3. 
 Prior studies found post-procedural mTICI score12-15, and >90% reperfusion on 
follow-up CTP were independent predictors of outcome24, but few studies have directly 
compared prognostication of mTICI scores and follow-up CTP performed in the same 
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patients.  These results suggest visual assessment of post-procedural DSA can distinguish 
patients with no reperfusion from patients with some reperfusion, but the degree of 
reperfusion is difficult to judge, and mTICI 3 may not accurately represent complete 
reperfusion on 24h CTP.  As a result, low mTICI scores performed similarly to SCTP for 
predicting poor outcome, but mTICI 2b/3 had poor specificity and PPV for predicting good 
outcome compared to SCTP>81.5%, mostly because 18% of mTICI 3 patients were not fully 
reperfused, leading to poor outcome.  Incomplete reperfusion following IAT in mTICI 3 
patients has been reported in prior studies finding tissue classified as salvageable on 
admission CTP were often infarcted on follow-up, even when complete reperfusion was 
achieved at an early time point25, and that infarct expansion between admission and 24h 
occurred in ~35% of mTICI 3 patients26. 
Perfusion on follow-up CTP may be overestimated by mTICI scores for several 
reasons.  The mTICI score requires neuroradiologists to assess perfusion of a 3D volume 
based on 2D projections, potentially leading to overestimation when well perfused regions 
overlap non-perfused regions; this is minimized when quantifying ischemic tissue on 3D-
CTP.  Furthermore, reperfusion of the affected territory on DSA is assessed by 
presence/absence of capillary blush9.  Degree of capillary blush constituting good 
perfusion, and size of the affected vascular territory may be subject to inter-rater 
variability; inter-rater variability is minimized by the threshold-based SCTP used in this 
study.  Lastly, capillary plugging by leukocyte adhesion27, platelet accumulation28, and/or 
lumen narrowing due to water accumulation in endothelial cells29 can lead to cerebral ‘no-
reflow phenomenon’, where capillary perfusion is impaired despite reperfusion of 
upstream arterioles.  Theoretically, no-reflow phenomenon would be better visualized 
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using CTP than DSA, since CTP parameters are calculated directly from contrast 
concentration changes in capillaries of each tissue voxel, as opposed to inferring tissue 
perfusion based on presence/absence of capillary blush.  This may explain why 9/49 mTICI 
3 patients had SCTP≤66.7% (Figure 4.3), although this could have also been caused by re-
embolization between post-procedural DSA and 24h CTP30-32. 
 This retrospective study had limitations.  Predicting poor outcome using 24h CTP 
has limited clinical value, since most penumbral tissue has likely progressed to infarction 
by this time, limiting effectiveness of additional interventions.  Furthermore, time delay 
between post-procedural DSA and 24h CTP introduced uncertainty, since the patients’ 
hemodynamic status may have changed between imaging sessions.  For example, mean 
SCTP in mTICI 0 patients was 27.0±12.1%; 35% (6/17) of these patients had SCTP>50%.  In 
these cases, disparities between mTICI score and SCTP were likely due to spontaneous clot 
lysis32 between post-procedural DSA and 24h CTP.  Similarly, 18% of mTICI 3 patients 
(9/49) had SCTP<67%; differences between mTICI score and SCTP could have been due to 
re-embolization between post-procedural DSA and 24h CTP, though studies suggest re-
embolization after IAT only occurs in ~10% of cases31-33.  Another study, prospectively 
designed to minimize time between post-procedural DSA and follow-up CTP, in a larger 
group of IAT-treated patients could address these limitations. 
 In summary, post-IAT mTICI 2b/3 did not reflect reperfusion seen on follow-up 
CTP, as a result, mTICI 2b/3 was not a specific marker of good outcome.  SCTP derived 
from pre- and post-procedural CTP scans was a better predictor of outcome than the 
commonly used mTICI score. 
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Chapter 5  
5 Conclusions and Future Work 
 The introduction to this thesis describes the pathophysiology, treatment, and 
medical imaging of AIS, with an emphasis placed on neuroimaging-based AIS triage and 
management.  As stated in the introduction, the main objective of this thesis was to identify 
limitations and potential areas for improvement in CTP-based selection of AIS patients 
who could benefit from IV t-PA or IAT and CTP-based outcome prognostication following 
treatment.  Specifically, a threshold for infarction after 3h of ischemia was developed using 
multimodal imaging in a porcine model of AIS, the impact of scan duration on quantitative 
CTP values and infarct volume derived by CBF thresholds was assessed, and the 
association between reperfusion on follow-up CTP and functional outcome was determined 
in IAT-treated AIS patients. 
 In this final chapter, major findings of this research and the implications for patient 
care will be discussed, an outline of possible future studies that should follow this work 
will be provided, and the major conclusions found from this work will be summarized. 
5.1 Summary 
5.1.1 Development of Porcine AIS Model and Derivation of 3h CBF 
Threshold for Infarction 
 Animal models of AIS are necessary to determine CTP-based CBF thresholds for 
different durations of ischemia because ischemia duration can be precisely controlled, a 
factor which is impossible to control in the clinical setting.  Additionally, CBF 
measurement and infarct delineation with gold standard imaging techniques can be 
performed contemporaneously, eliminating uncertainties due to infarct expansion between 
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the acute phase and follow-up imaging, which is often performed 1-7 days post symptom 
onset in patients.  As mentioned in Section 1.5, AIS models implemented in large animals, 
such as pigs, are a better representation of human stroke because of their gyrencephalic 
brain, and proportions of gray/white matter that are more similar to humans.  However, the 
rete mirabile makes commonly used intra-luminal procedures for inducing cerebral 
ischemia impossible in pigs and other large mammals1, so most models require invasive 
surgical procedures2,3 that make it difficult to maintain the animal at its basal physiological 
state after stroke induction. 
 The ET-1 based porcine model of AIS presented in Chapter 2 requires only an 
incision on the scalp and drilling of a small burr hole through the skull.  This less invasive 
approach is advantageous compared to craniectomy-based approaches used in prior 
studies, which resulted in subarachnoid hemorrhage, ligature failure, and other technical 
problems in ~40% of animals4; similar complications did not occur in any of the 11 animals 
used in our study.  Using this model, we were able to derive an absolute CBF threshold of 
12.6 mL∙min-1∙100g-1 for infarction after 3h of ischemia, which agreed with the 3h CBF 
threshold for infarction derived in the previously mentioned study using a more invasive 
AIS model in monkeys (12 mL∙min-1∙100g-1)4. 
5.1.2 Assessment of Scan Duration Effect on Quantitative CTP 
Results 
 Despite more widespread use of CTP for AIS applications, the optimal CTP scan 
duration for imaging the ischemic brain has yet to be comprehensively determined.  
Shortening scan duration is beneficial to the patient because it decreases radiation dose.  
However, if the CTP scan is too short to fully capture delayed contrast washout from 
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ischemic tissue it can cause errors in estimated CTP parameters5,6, which could cause over- 
or underestimated threshold-derived infarct volumes, and therefore errors in AIS patient 
triaging.  Understanding how scan duration impacts CTP parameters and threshold-derived 
infarct volumes is important to ensure that CTP-based triaging of AIS patients is accurate, 
and reproducible between hospitals which may use different durations for brain CTP scans. 
 In Chapter 3 we determined the effect of scan duration on CBV, CBF, and Tmax 
values, in normal and ischemic tissue, calculated by GE Healthcare’s commercially 
available software (CTP4D, GE Healthcare, Waukesha, WI), for durations ranging from 
40s to 150s.  Optimal scan durations for two time-dependent CBF thresholds for infarction 
previously derived by our group, which minimized radiation dose without infarct volumes 
being affected by truncation artifacts, were also derived.  We found that CBV and Tmax 
were strongly dependent on scan duration, with median values decreasing by as much as 
43% and 44% (relative to the median value from the 150s scan) respectively in ischemic 
tissue, and 29% and 26% respectively in contralateral normal tissue, whereas CBF was 
independent of scan duration, with the median value changing by only 1.4 to 6.5%.  
Furthermore, infarct volumes derived by both time-dependent CBF thresholds for 
infarction were found to be equivalent, within ±2mL, across the entire range of scan 
durations investigated, meaning that scan duration can be decreased to 40s to minimize the 
radiation dose to patients when CBF thresholds are used to estimate infarct volume.  For 
the 2-phase CTP protocol used in this study, this would remove the entire 2nd phase and 
one-third of the 1st phase of the scan, decreasing radiation dose by ~48%. 
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5.1.3 Follow-up CTP as a Prognosticator of Functional Outcome in 
IAT-Treated Patients 
 The degree of reperfusion following IAT is commonly assessed by applying the 
mTICI scale to post-procedural DSA, with scores of 2b and 3 thought to represent near-
complete and complete reperfusion of the previously ischemic tissue, respectively7  
However, ~15-35% of patients in the treatment arm of clinical trials of IAT who had post-
procedural mTICI scores of 2b/3 still went on to have poor functional outcomes8-14, 
suggesting DSA may not accurately assess reperfusion after treatment.  As neuroprotection 
advances, accurately assessing reperfusion following IAT may become important for 
identifying the patients most likely to benefit from neuroprotective drugs or therapies. 
 In Chapter 4, the accuracy of reperfusion assessed using mTICI scores on post-
procedural DSA was investigated by comparison to a reperfusion score (SCTP) derived from 
pre- and post-treatment CTP, and the two metrics were compared as predicters of 90-day 
functional outcome in IAT-treated AIS patients.  We found that SCTP was similar between 
patients with post-procedural mTICI scores of 2a (67.7 ± 10.9%), 2b (72.8 ± .5%), and 3 
(82.6 ±2.7%), revealing that post-procedural mTICI scores of 3 may not necessarily reflect 
complete reperfusion on 24h follow-up CTP, and suggesting that although visual 
assessment of DSA can differentiate patients with no reperfusion from those with some 
reperfusion, it may not be able to accurately infer the degree of reperfusion.  We also found 
that SCTP was a significantly better predictor of functional outcome than post-procedural 
mTICI score; the optimal SCTP threshold derived in the study (SCTP > 81.5%) predicted 
good functional outcome with better specificity (0.69 versus 0.41), accuracy (0.71 versus 
0.61), and PPV (0.67 versus 0.56) compared to mTICI 2b/3. 
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5.2 Experimental and Clinical Impact 
 Patients arriving at the hospital after the population-based time windows for IV t-
PA (4.5h) or IAT (6h), or those with unknown onset times were previously ineligible for 
treatment, but results from recent clinical trials show that eligibility for IV t-PA in patients 
with unknown onset time can be determined based on FLAIR-DWI mismatch15, and 
eligibility for IAT can be determined with infarct/penumbra14 or clinical/imaging 
mismatch13 assessed on CTP post-processed with RAPID, up to 24h post onset (detailed in 
Chapters 1.3 and 1.4).  This represents a significant step towards more personalized care 
for AIS patients, but patient selection was not perfect in these trials (~50% of patients in 
the IAT arm of DAWN and DEFUSE 3 had poor functional outcomes13,14); incorporating 
time-dependent CBF thresholds for infarction could potentially improve patient selection 
by providing more precise definition of the infarct core at different times since symptom 
onset.  Besides estimating admission infarct volume, applying multiple thresholds for 
different ischemia durations from admission CTP-CBF maps could be used to predict the 
increase in infarct volume over time.  This could inform decisions regarding inter-hospital 
transfer of patients being considered for IAT, by using the estimated increase in infarct 
volume to predict whether the patient would still be eligible for IAT based on 
infarct/penumbra or clinical/imaging mismatch criteria upon arrival.  The animal study 
described in Chapter 2 derived a CBF threshold for infarction after 3 hours of ischemia, if 
similar thresholds were derived for a range of ischemia durations then this type of analysis 
could become feasible.   The findings of Chapter 2 are complemented by the findings of 
Chapter 3, that quantitative CBF values from CTP are independent of scan duration, for 
scans 40s or longer, and that infarct volumes derived by CBF thresholds are equivalent, 
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within ±2mL, across scan durations ranging from 40s to 150s.  Therefore, CTP scan 
duration can be shortened to 40s to decrease radiation dose to patients by ~48%, without 
truncation artifacts affecting AIS patient triaging decisions made based on infarct volumes 
derived by time-dependent CBF thresholds. 
 Another important finding from this thesis is that reperfusion assessed on follow-
up CTP is a more accurate indicator of 90-day functional outcome than mTICI scores 
assessed on post-procedural DSA.  Post-treatment reperfusion estimated by mTICI score 
is commonly used to compare different revascularization therapies or IAT devices.  Our 
findings suggest that follow-up CTP should be used for these comparisons instead, since 
follow-up CTP provides more accurate quantification of post-treatment reperfusion and is 
more strongly associated with outcome than the commonly used mTICI score.  As 
neuroprotective drugs and therapies continue to improve, these findings could take on even 
greater importance as a method of identifying patients with incomplete reperfusion who 
would most likely benefit from additional therapies. 
5.3 Future Work 
 This thesis suggests several directions of further investigations into the applications 
of perfusion imaging in AIS, some of these directions are discussed in this section.    
5.3.1 Deriving CBF Thresholds for a Greater Range of Ischemia 
Durations 
 The main limitation of the ET-1 porcine AIS model used in Chapter 2 was that the 
cerebral ischemia in the distal MCA territory was not highly reproducible between animals 
and did not mimic LVO in patients, this was likely because ET-1 was not injected in the 
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immediate vicinity of the proximal MCA in all cases.  With improved localization of the 
MCA using TDCs from dynamic CTP images (Figure 5.1), it should be possible to inject 
ET-1 close to the origin of the MCA, thus producing a proximal constriction more similar 
to LVO.  Furthermore, the ischemic territory will be more reproducible, and we will be 
able to extend the ischemia duration well beyond 3h with repeated ET-1 injections at the 
same site.  This would allow absolute CBF thresholds for infarction to be derived for a 
greater range of ischemia durations using a similar procedure to what was used in Chapter 
2 but changing the duration between the ET-1 injection and the start of 18F-FFMZ PET 
imaging.  This could be performed in several groups of animals, each with a different time 
interval between ET-1 injection and infarct imaging, or alternatively, FMZ labelled with 
11C (half-life ~20 minutes) could be used, since the shorter half-life could allow the infarct 
to be delineated at multiple time points in the same animals.  
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Figure 5.1: Localization of MCA in porcine AIS model with dynamic images from 
CTP 
 
Fig. 5.1: Targeting the right MCA for ET-1 injection to induce stroke.  (A) CTP image at 
time of maximal contrast enhancement in arteries and proximal veins; (C) same image as 
(A) but in bone window to show the anatomical landmarks of the skull and carotid rete 
mirabile; (B) TDCs from ROI 1-6 including the R ICA, MCA and proximal veins. 
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5.3.2 Using PS to Identify Patients at Increased Risk of 
Hemorrhagic Transformation 
 To further improve CTP-based patient selection for IV t-PA or IAT, methods for 
identifying patients at increased risk of hemorrhagic transformation could be developed 
based on assessing BBB permeability using PS maps from admission CTP.  PS thresholds 
could be established based on the average PS within the infarct, or the volume of tissue 
within the infarct with elevated PS (relative to the contralateral side). 
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Figure 5.2: Elevated PS in patient with hemorrhagic transformation after IAT 
 
Fig. 5.2: Average image (left), CBF map (middle), and PS map (right) from admission 
CTP of a 46-year-old, male patient with occlusion of the M1 segment of the right MCA, 
who was treated with IAT but had grade 2 parenchymal hematoma on 7-day follow-up 
imaging.  Elevated PS is seen throughout the ischemic tissue in the right MCA territory on 
admission CTP. 
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5.3.3 Assessment of Post-IAT Reperfusion using ‘DSA Perfusion’ 
Maps 
 In Chapter 4 we found that follow-up CTP provides more accurate assessment of 
post-thrombectomy reperfusion compared to post-procedural mTICI scores assessed on 
DSA and was a more accurate predictor of functional outcome.  However, performing 
follow-up CTP requires transferring the patient from the angiography suite to a CT scanner, 
it would be more advantageous if there was a similar method of assessing reperfusion 
which could be performed in the angiography suite.  Our group has recently created 
software capable of producing perfusion maps from dynamic DSA acquisitions (Figure 
5.3).  This would provide a more quantitative, less subjective alternative to the mTICI score 
for assessing reperfusion on post-procedural DSA.  If the accuracy for predicting functional 
outcomes using this new technique is similar to what was observed using follow-up CTP 
in Chapter 4, then ‘DSA perfusion’ maps could improve outcome prediction after IAT 
without the need for additional follow-up CTP to be performed. 
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Figure 5.3: Blood flow maps derived from DSA (anterior-posterior view) 
 
Fig. 5.3: Blood flow maps derived from DSA before (left) and after thrombectomy (right), 
shown in the anterior-posterior view.  Black arrow in pre-IAT CBF map shows occlusion 
of MCA resulting in ischemic downstream tissue.  After IAT, flow in the MCA and 
downstream tissue was been restored. 
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5.4 Conclusion 
 In summary, the significant findings of this thesis include: 
1. As shown in a porcine model of AIS, tissue with CBF < 12.6 mL∙min-1∙100g-1 will 
progress to infarction after 3h of ischemia. 
2. CBV and Tmax values computed with commercially available CTP software depend 
on the duration of the CTP scan, whereas CBF is independent of the scan duration.  
By extension, infarct volumes derived by time-dependent CBF thresholds are 
equivalent, within ±2mL, over a range of scan durations from 40s to 150s. 
3. Reperfusion assessed on follow-up CTP is a more accurate predictor of 90-day 
functional outcome in IAT-treated AIS patients than mTICI scores from post-
procedural DSA. 
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Appendices 
Appendix A: Supplementary Figures for Chapter 2 
Figure A.1: CBF Histograms for each Animal 
 
Fig. A.1: Frequency distributions of CBF values from infarct (blue) and 
penumbra/oligemia tissue (yellow) for each of the 6 animals from Chapter 2. 
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Figure A.2: 18F-FFMZ PET and CBF maps from Animal 1 
 
Fig A.2: 18F-FFMZ PET and CBF maps from 30, 60, and 120min post ET-1 injection in 
slice with the largest extent of infarct in Animal 1. 
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Figure A.3: 18F-FFMZ PET and CBF maps from Animal 2 
 
Fig A.3: 18F-FFMZ PET and CBF maps from 30, 60, and 120min post ET-1 injection in 
slice with the largest extent of infarct in Animal 2. 
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Figure A.4: 18F-FFMZ PET and CBF maps from Animal 3 
 
Fig A.4: 18F-FFMZ PET and CBF maps from 30, 60, and 120min post ET-1 injection in 
slice with the largest extent of infarct in Animal 3. 
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Figure A.5: 18F-FFMZ PET and CBF maps from Animal 4 
 
Fig A.5: 18F-FFMZ PET and CBF maps from 30, 60, and 120min post ET-1 injection in 
slice with the largest extent of infarct in Animal 4. 
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Figure A.6: 18F-FFMZ PET and CBF maps from Animal 5 
 
Fig A.6: 18F-FFMZ PET and CBF maps from 30, 60, and 120min post ET-1 injection in 
slice with the largest extent of infarct in Animal 5. 
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Figure A.7: 18F-FFMZ PET and CBF maps from Animal 6 
 
Fig A.7: 18F-FFMZ PET and CBF maps from 30, 60, and 120min post ET-1 injection in 
slice with the largest extent of infarct in Animal 6. 
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Appendix B: Animal Ethics Approval for the work contained in Chapter 2 
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Appendix C: Ethics Approval for the work contained in Chapter 3 
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